var title_f19_41_20112="Palpating plantar fascia PI";
var content_f19_41_20112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpating the plantar fascia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The toes are grasped and dorsiflexed with one hand, while the other hand palpates the plantar aspect of the foot, particularly the bands compressing the plantar fascia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert P Sheon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20112=[""].join("\n");
var outline_f19_41_20112=null;
var title_f19_41_20113="Hemoglobin H disease";
var content_f19_41_20113=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemoglobin H disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with hemoglobin H disease and an intact spleen. The smear shows target cells (blue arrows), microcytic red cells (black arrow), and red cell fragments (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20113=[""].join("\n");
var outline_f19_41_20113=null;
var title_f19_41_20114="Echocardiogram Ebstein I";
var content_f19_41_20114=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Echocardiography of Ebstein anomaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two dimensional echocardiogram in the apical 4 chamber view (panel A) from a patient with Ebstein anomaly shows a displaced, long (\"sail\"-like) anterior leaflet of the tricuspid valve, which is attached to the tricuspid annulus (red arrow) and apical displacement of the septal leaflet (white arrow). Note the large right atrialized (RA) portion of the right ventricle (RV). Color Doppler echocardiogram (panel B) shows severe tricuspid regurgitation originating at the level of the displaced tricuspid valve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20114=[""].join("\n");
var outline_f19_41_20114=null;
var title_f19_41_20115="Port sites for laparoscopic pancreatectomy";
var content_f19_41_20115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Port sites for laparoscopic pancreatectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 493px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20115=[""].join("\n");
var outline_f19_41_20115=null;
var title_f19_41_20116="Depression in adults";
var content_f19_41_20116=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Depression in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/41/20116/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20116/contributors\" id=\"au1135\">",
"       Jeffrey M Lyness, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/41/20116/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20116/contributors\" id=\"se7050\">",
"       Thomas L Schwenk, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/41/20116/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20116/contributors\" id=\"de3194\">",
"       David Solomon, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?19/41/20116?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DEPRESSION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Depression is a medical condition that can cause a wide variety of psychological and physical symptoms. Extreme sadness is often the most pronounced symptom. Some people experience loss of interests or pleasure rather than sadness. Depression can be distinguished from occasional blues and grief because depression is persistent, often interfering with daily activities and relationships.",
"    </p>",
"    <p>",
"     In the past, depression was poorly understood and carried an unfortunate social stigma. However, depression occurs commonly; the risk of suffering from a major depressive episode at some time during a person's life is up to 12 percent for men and 25 percent for women. The condition can affect people of all ages, including children and older adults.",
"    </p>",
"    <p>",
"     Depression is a treatable condition. Psychotherapy (counseling), drug therapy, and other treatments can alleviate symptoms and help people with depression return to rich and productive lives. Treatment is most successful in people who are open to being helped and willing to participate in treatment.",
"    </p>",
"    <p>",
"     This article discusses the causes, risk factors, signs and symptoms, and diagnosis of depression. A separate article discusses the treatment of depression. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about depression is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"      \"Clinical manifestations and diagnosis of depression\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"      \"Diagnosis and management of late-life depression\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"      \"Initial treatment of depression in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"      \"Treatment of resistant depression in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Articles that discuss depression in adolescents are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"      \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"      \"Patient information: Depression treatment options for adolescents (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DEPRESSION CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Research has helped clarify the complex biologic basis of depression, although the exact cause of depression is still uncertain. Studies suggest that depression is accompanied by changes in neurochemicals in the brain, including serotonin, norepinephrine, and dopamine. These neurochemicals allow cells to communicate with each other and play an essential role in all brain functions, including movement, sensation, memory, and emotions. That depression affects the brain is supported by the results of genetic studies and the response of depression to drug therapy and other therapies that alter levels of brain neurochemicals.",
"    </p>",
"    <p>",
"     In addition, social factors may be involved, including isolation and criticism from family members. Psychological factors include repeated negative thoughts (for example, &ldquo;I&rsquo;m no good,&rdquo; &ldquo;The future is hopeless,&rdquo; or &ldquo;There is nothing I can do&rdquo;). Losses and interpersonal problems may also contribute to onset of depression.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DEPRESSION RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Although anyone can develop depression, certain factors increase a person's risk for this condition, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Female sex",
"      </li>",
"      <li>",
"       A history of depression in a parent, sibling, or child",
"      </li>",
"      <li>",
"       A prior episode of major depression",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other factors have been identified as secondary (weaker) risk factors for depression:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A history of depression in a family member who is not a parent, sibling, or child",
"      </li>",
"      <li>",
"       Lack of social supports",
"      </li>",
"      <li>",
"       Significant stressful life events",
"      </li>",
"      <li>",
"       Current alcohol or substance abuse",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Depression and other medical conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with chronic medical or neurological disorders, as well as some people with short term conditions, have difficulty with depression. The number of people with depression may be particularly high in diseases of the brain (eg, stroke, traumatic brain injury, Parkinson disease), heart conditions, cancer, and conditions that affect the immune system (eg, lupus).",
"    </p>",
"    <p>",
"     The risk of depression is not related to any specific disease or organ system. However, depression can worsen the outcome of many conditions, and even increases the risk of death from medical causes as well as suicide. This may be related to the fact that some people with depression are not motivated to take their medications on schedule, attend medical appointments,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     exercise.",
"    </p>",
"    <p>",
"     Fortunately, recognizing and treating depression can improve a person's sense of health and well-being, and can also improve a person's interest in caring for him or herself.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DEPRESSION SYMPTOMS/DEFINITIONS",
"     </span>",
"    </p>",
"    <p>",
"     Extreme sadness may be the best known symptom of depression, although depression also includes other psychological and physical symptoms. The hallmark of depression is that symptoms are persistent and interfere with daily activities and relationships.",
"    </p>",
"    <p>",
"     Unfortunately, there is no single sign or symptom that serves as a marker for depression, and the condition can be tricky to identify. In fact, many people do not recognize that they are depressed or that their physical symptoms (aches and pain, appetite and sleep changes) are related to depression. One study revealed that 29 percent of people visiting their doctors for a physical symptom had a depressive disorder or an anxiety disorder [",
"     <a class=\"abstract\" href=\"UTD.htm?19/41/20116/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The symptoms of the three types of depression (major depression, dysthymia, and atypical depression) will be discussed here.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Major depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Major depression is the medical term for depression that includes five of the symptoms listed below. A person can have mild, moderate, or severe major depression.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Sadness most of the day, particularly in the morning",
"      </li>",
"      <li>",
"       Markedly diminished pleasure or loss of interest in almost all activities nearly every day",
"      </li>",
"      <li>",
"       Significant weight loss or weight gain",
"      </li>",
"      <li>",
"       Insomnia or excessive sleep",
"      </li>",
"      <li>",
"       Agitated movements or very slow movement",
"      </li>",
"      <li>",
"       Fatigue or loss of energy",
"      </li>",
"      <li>",
"       Feelings of worthlessness or guilt",
"      </li>",
"      <li>",
"       Impaired concentration and indecisiveness",
"      </li>",
"      <li>",
"       Recurring thoughts of death or suicide",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The symptoms must be present during the same time period and must persist for at least two weeks. One of the symptoms must be either depressed mood or loss of interest.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Dysthymia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dysthymia is a low-grade depression that persists for a long period of time. Dysthymia is usually diagnosed when a person has had depressive symptoms for at least two consecutive years. The most common symptoms of dysthymia include an absence of pleasure or interest in activities, low self-esteem, and low energy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Atypical depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Atypical depression is a common type of depression. People with atypical depression have some of the same features of major depression listed above, but do not have five of the nine symptoms required for a diagnosis of major depression. Instead, they often have prominent physical symptoms, including weight gain and sleep disturbances, especially excessive sleep.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Seasonal affective disorder",
"     </span>",
"     &nbsp;&mdash;&nbsp;Seasonal affective disorder (SAD) is a form of major depression that varies with the seasons. Most patients with SAD have episodes of depression that begin in the fall and continue through the winter.",
"    </p>",
"    <p>",
"     SAD is characterized by several features:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Symptoms of depression that regularly appear during a particular time of year (unrelated to stressful events associated with specific seasons)",
"      </li>",
"      <li>",
"       Full remission of depression (or a change from depression to mania) during other times of year",
"      </li>",
"      <li>",
"       Two major episodes of depression during the associated season in the last two years and an absence of depression during other times of the year",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Grief",
"     </span>",
"     &nbsp;&mdash;&nbsp;Grief is a normal reaction to many situations, following the death of a loved one, loss of a close relationship or job, or the loss of health or independence. This section discusses one of the most common types of grief that occurs after the death of a family member or friend.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Grief following death",
"     </span>",
"     &nbsp;&mdash;&nbsp;Immediately following death, whether or not the death has been anticipated, survivors usually experience feelings of numbness, shock, and disbelief. Intense feelings of sadness, yearning for the deceased, anxiety about the future, disorganization, and emptiness commonly arise in the weeks after the death.",
"    </p>",
"    <p>",
"     \"Searching behaviors,\" including visual and auditory hallucinations of the deceased person, are common and may lead the bereaved person to fear that he or she is \"going crazy.\" Despair and sadness are common as it becomes clear that the deceased will not return. Sleeplessness, appetite disturbances, agitation, chest tightness, sighing, and exhaustion are common.",
"    </p>",
"    <p>",
"     These reactions are usually transient and resolve in over 90 percent of people by 13 months after the loss. However, losses can trigger depression in some people; as an example, 15 to 35 percent of people who lose their spouse develop depression in the following year [",
"     <a class=\"abstract\" href=\"UTD.htm?19/41/20116/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Some patients who grieve may develop complicated grief (or traumatic grief), which is defined as persistence of at least four of the following feelings for six months or more:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <span class=\"nowrap\">",
"        Numbness/detachment",
"       </span>",
"      </li>",
"      <li>",
"       Bitterness",
"      </li>",
"      <li>",
"       Feelings that life is empty without the deceased",
"      </li>",
"      <li>",
"       Trouble accepting the death",
"      </li>",
"      <li>",
"       A sense that the future holds no meaning without the deceased",
"      </li>",
"      <li>",
"       Being on edge or agitated",
"      </li>",
"      <li>",
"       Difficulty trusting others since the loss",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Grief versus depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is often difficult to know if a person who is grieving also suffers from depression. Patients who have feelings of hopelessness, helplessness, worthlessness, and guilt, as well as severe symptoms of early grief may be depressed. Patients whose grief is complicated by depression often benefit from an antidepressant medication in addition to individual or group psychotherapy. Group therapy in a bereavement group can be particularly useful for patients with grief and depression. In contrast, persons suffering only with grief are more likely to benefit from psychotherapy alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Bipolar depression",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with bipolar I disorder (manic depression) have periods of mania (feeling excessively elated, impulsive, irritable, or irrational), and may also experience periods of major depression. Bipolar II disorder involves periods of depression interspersed with periods of \"hypomania,\" which are milder forms of mania with periods of high energy, decreased sleep, and some agitation. People with bipolar II disorder may have a poor response to antidepressant medications; consultation with a psychiatrist is recommended to assist in the treatment of people with this disorder. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"      \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      DEPRESSION DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of depression is based upon a patient's symptoms, the duration of symptoms, and the overall effects of these symptoms on a patient's life. There is currently no medical test that identifies depression, although blood tests are often done to rule out other medical conditions that could be causing depression (such as hypothyroidism).",
"    </p>",
"    <p>",
"     A diagnosis of major depression requires that symptoms are severe enough to interfere with a person's daily activities, and the ability to take care of oneself, maintain relationships, engage in work activities, and to support oneself. A diagnosis also requires that the symptoms have occurred on a daily basis for at least two weeks. The diagnosis should be made by a physician or advanced clinician, based upon the patient&rsquo;s history and findings from an examination (sometimes also supplemented with laboratory testing).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      DEPRESSION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A separate topic review discusses treatment options for adults with depression. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H161\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6663737\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=see_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37106?source=see_link\">",
"      Patient information: Electroconvulsive therapy (ECT) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/16/25858?source=see_link\">",
"      Patient information: Anorexia nervosa (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/37/26194?source=see_link\">",
"      Patient information: Bulimia nervosa (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=see_link\">",
"      Patient information: Post-traumatic stress disorder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/9/41105?source=see_link\">",
"      Patient information: Postpartum depression (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/30/33249?source=see_link\">",
"      Patient information: Antisocial personality disorder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/51/2866?source=see_link\">",
"      Patient information: Seasonal affective disorder (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/18/11554?source=see_link\">",
"      Patient information: When you have depression and another health problem (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/482?source=see_link\">",
"      Patient information: Serotonin syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6663845\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/21/29013?source=see_link\">",
"      Patient information: Depression treatment options for adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7574?source=see_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/33/26135?source=see_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38858?source=see_link\">",
"      Assessment and management of depression in palliative care",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29735?source=see_link\">",
"      Depression in pregnant women: Clinical features and consequences",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27673?source=see_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"      Overview of psychosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17014?source=see_link\">",
"      Postpartum psychosis: Epidemiology, clinical manifestations, and assessment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=see_link\">",
"      Treatment of postpartum psychosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=see_link\">",
"      Seasonal affective disorder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Mental Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nimh.nih.gov/\">",
"      www.nimh.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Psychiatric Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.psych.org/\">",
"      www.psych.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Psychological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.apa.org/\">",
"      www.apa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Child and Adolescent Psychiatry",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aacap.org/\">",
"      www.aacap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Depression and Bipolar Support Alliance (DBSA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"      www.DBSAlliance.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Foundation For Depressive Illness",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.depression.org/\">",
"      www.depression.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Mental Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nmha.org/\">",
"      www.nmha.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Alliance for the Mentally Ill",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nami.org/\">",
"      www.nami.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?19/41/20116/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?19/41/20116?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20116/abstract/1\">",
"      Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. Am J Med 1997; 103:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20116/abstract/2\">",
"      Zisook S, Shuchter SR. Depression through the first year after the death of a spouse. Am J Psychiatry 1991; 148:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20116/abstract/3\">",
"      Gilbody S, Sheldon T, Wessely S. Should we screen for depression? BMJ 2006; 332:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20116/abstract/4\">",
"      Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:765.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f19_41_20116=[""].join("\n");
var outline_f19_41_20116=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DEPRESSION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DEPRESSION CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DEPRESSION RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DEPRESSION SYMPTOMS/DEFINITIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           DEPRESSION DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           DEPRESSION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20117="Phentermine: Patient drug information";
var content_f19_41_20117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phentermine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=see_link\">",
"     see \"Phentermine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adipex-P&reg;;",
"     </li>",
"     <li>",
"      Suprenza&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat obesity.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phentermine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Both attention deficit/hyperactivity problems and Tourette's syndrome or tics, high blood sugar (diabetes), drug abuse, glaucoma, heart disease, high blood pressure, nervous state, overactive thyroid disease, or structure problems of the heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698413",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often if you have heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablets and capsules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take before breakfast or 1 to 2 hours after breakfast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695516",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place on your tongue and let it melt. Water is not needed. Do not swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11271 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20117=[""].join("\n");
var outline_f19_41_20117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209145\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019511\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019510\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019515\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019516\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019518\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019513\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019514\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019519\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019520\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26118?source=related_link\">",
"      Phentermine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20118="Sulfadiazine: Drug information";
var content_f19_41_20118=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfadiazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/25/43412?source=see_link\">",
"    see \"Sulfadiazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"    see \"Sulfadiazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Sulfonamide Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"     Oral: 2-4 g/day in 3-6 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatic fever prophylaxis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;30 kg: 0.5 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;30 kg: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Toxoplasma gondii",
"      </i>",
"     </b>",
"     <b>",
"      encephalitis (HIV-exposed/-positive patients) (CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acute therapy",
"     </i>",
"     (duration of therapy: &ge;6 weeks): 1000 mg (&lt;60 kg) or 1500 mg (&ge;60 kg) every 6 hours in combination with pyrimethamine plus leucovorin calcium (preferred)",
"     <b>",
"      or",
"     </b>",
"     alternatively, may give 1000-1500 mg every 6 hours in combination with atovaquone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prophylaxis to prevent recurrence:",
"     </i>",
"     2000-4000 mg/day in 2-4 divided doses in combination with pyrimethamine and leucovorin calcium (preferred)",
"     <b>",
"      or",
"     </b>",
"     alternatively, may give 2000-4000 mg/day in 2-4 divided doses in combination with atovaquone",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"      see \"Sulfadiazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"     Oral: Children &gt;2 months of age: Initial: 75 mg/kg; Maintenance: 150 mg/kg/day in 4-6 divided doses (maximum: 6 g/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatic fever prophylaxis:",
"     </b>",
"     Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;30 kg: 0.5 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;30 kg: 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis  (HIV-exposed/-positive patients) (CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Congenital toxoplasmosis:",
"     </i>",
"     Infants: 100 mg/kg/day in divided doses every 12 hours for 12 months in combination with pyrimethamine plus leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Acquired toxoplasmosis:",
"     </i>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute induction therapy: 25-50 mg/kg/dose given 4 times/day (maximum: 1-1.5 g/dose) in combination with pyrimethamine and leucovorin calcium. Continue acute induction therapy for &ge;6 weeks, then follow with chronic suppressive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis to prevent recurrence (prior to encephalitis): 85-120 mg/kg/day divided every 6-12 hours (maximum: 2-4 g/day) in combination with pyrimethamine plus leucovorin calcium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Toxoplasma gondii encephalitis:",
"     </i>",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with at least 8 ounces of water and around-the-clock to promote less variation in peak and trough serum levels. Oral sodium bicarbonate may be used to alkalinize the urine of patients unable to maintain adequate fluid intake (in order to prevent crystalluria, azotemia, oliguria) (Lerner, 1996).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of the following conditions (per product labeling): Chancroid, trachoma, inclusion conjunctivitis, nocardiosis, urinary tract infections, toxoplasmosis encephalitis, malaria, meningococcal meningitis, acute otitis media, rheumatic fever (prophylaxis), meningitis (adjunctive)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Refer to current guidelines for appropriate use.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       SulfADIAZINE may be confused with sulfaSALAzine, sulfiSOXAZOLE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Allergic myocarditis, periarteritis nodosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, chills, convulsions, depression, fever, hallucinations, headache, insomnia, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Epidermal necrolysis, erythema multiforme, exfoliative dermatitis, photosensitivity, pruritus, purpura, rash, skin eruptions, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, thyroid function disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, pancreatitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria, stone formation, toxic nephrosis with oliguria and anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytopenia, aplastic anemia, hemolytic anemia, hypoprothrombinemia, leukopenia, methemoglobinemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctival/scleral injection, periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, lupus erythematosus, serum sickness-like reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any sulfa drug or any component of the formulation; children &lt;2 months of age unless indicated for the treatment of congenital toxoplasmosis; pregnancy (at term); breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred; discontinue use at first sign of rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergies/asthma: Use with caution in patients with allergies or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose 6-phosphate dehydrogenase (G6PD) deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification required. Maintain adequate hydration to prevent crystalluria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not for the treatment of group A beta-hemolytic streptococcal infections.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F223797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sulfonamide Derivatives may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Sulfonamide Derivatives may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Sulfonamide Derivatives may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Sulfonamide Derivatives may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procaine: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Sulfonamide Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonamide Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F223773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Avoid large quantities of vitamin C or acidifying agents (cranberry juice) to prevent crystalluria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai, St John's wort (may also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8774446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies sulfadiazine as pregnancy category C. Sulfadiazine crosses the placenta. Available studies and case reports have failed to show an increased risk for congenital malformations after use. Sulfadiazine is indicated for use in children &lt;2 months of age for the treatment of congenital toxoplasmosis and may be used in pregnancy for the maternal treatment of",
"     <i>",
"      Toxoplasmic gondii",
"     </i>",
"     encephalitis and as an alternative agent for the secondary prevention of rheumatic fever. Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, sulfadiazine is contraindicated by the manufacturer for use near term. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8774449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfadiazine distributes into human milk. Per the manufacturer, sulfadiazine is contraindicated in nursing mothers since sulfonamides cross into the milk and may cause kernicterus in the newborn. Because sulfadiazine has therapeutic indications for infants &ge;2 months of age, kernicterus after exposure via breast-feeding would not be expected in healthy infants of this age group; however, sulfonamides should not be used while nursing an infant with G6PD deficiency or hyperbilirubinemia. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F223766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supplemental leucovorin calcium should be administered to reverse symptoms or prevent problems due to folic acid deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SulfADIAZINE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $428.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12925088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perform culture and sensitivity testing prior to initiating therapy; frequent CBC and urinalysis during therapy; signs of serious blood disorders (sore throat, fever, pallor, purpura, jaundice); CD4+ count in HIV-exposed/-positive patients treated for toxoplasmosis; sulfonamide blood concentrations may be monitored for severe infections (target: 12-15 mg/100 mL)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adiazin (FI);",
"     </li>",
"     <li>",
"      Adiazine (FR);",
"     </li>",
"     <li>",
"      Labdiazina (PT);",
"     </li>",
"     <li>",
"      Sulfadiazin Streuli (CH);",
"     </li>",
"     <li>",
"      Sulfadiazin-Heyl (DE);",
"     </li>",
"     <li>",
"      Sulfadiazina (IT);",
"     </li>",
"     <li>",
"      Sulfadiazina Reig Jofre (ES);",
"     </li>",
"     <li>",
"      Sulfadiazine (GB);",
"     </li>",
"     <li>",
"      Sulfadiazine Suspensie FNA (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Throughout body tissues and fluids including pleural, peritoneal, synovial, and ocular fluids; throughout total body water; readily diffused into CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 38% to 48%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Via N-acetylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Within 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (43% to 60% as unchanged drug, 15% to 40% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, \"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute",
"      <i>",
"       Streptococcal pharyngitis",
"      </i>",
"      : A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,\" Circulation, 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan JE, Benson C, Holmes KH, et al, \"Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katlama C, De Wit S, O'Doherty E, et al, &ldquo;Pyrimethamine-Clindamycin vs Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients With AIDS,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(2):268-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/8838183/pubmed\" id=\"8838183\" target=\"_blank\">",
"        8838183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lerner PI, \"Nocardiosis,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(6):891-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/8783685/pubmed\" id=\"8783685\" target=\"_blank\">",
"        8783685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porter SB and Sande MA, &ldquo;Toxoplasmosis of the Central Nervous System in the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(23):1643-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/1359410/pubmed\" id=\"1359410\" target=\"_blank\">",
"        1359410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torre D, Casari S, Speranza F, et al, &ldquo;Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1346-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20118/abstract-text/9624473/pubmed\" id=\"9624473\" target=\"_blank\">",
"        9624473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9960 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-C2C579228A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20118=[""].join("\n");
var outline_f19_41_20118=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223802\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223778\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223791\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223779\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223759\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223745\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803230\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223760\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223809\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223800\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223764\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223749\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223754\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223773\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223756\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223783\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8774449\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223766\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524726\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12925088\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038834\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223748\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223763\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/25/43412?source=related_link\">",
"      Sulfadiazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=related_link\">",
"      Sulfadiazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20119="Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation";
var content_f19_41_20119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20119/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20119/contributors\">",
"     David M Fleischer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20119/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20119/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/41/20119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term allergy refers to a hypersensitivity reaction initiated by immunologic mechanisms. Three factors are needed to develop allergic disease: the appropriate genetic background, contact with the allergen(s), and environmental factors.",
"   </p>",
"   <p>",
"    The most prevalent allergic or atopic disorders include atopic dermatitis (AD), allergic asthma, allergic rhinitis (AR), and food allergies. These conditions afflict 20 percent of the population of the United States, and their prevalence is rising in developed nations. The increase in atopic diseases has been recognized as a pandemic, thus emphasizing the need for effective allergy prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three types of allergy prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prevention, which blocks the initial immunologic sensitization (ie, the development of IgE specific to an allergen)",
"     </li>",
"     <li>",
"      Secondary prevention, which reduces the development of further disease after sensitization",
"     </li>",
"     <li>",
"      Tertiary prevention, which reduces symptoms after disease expression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Convincing studies support the existence of a critical time early in infancy, and possibly even in prenatal life, in which the genetically predisposed atopic infant is at higher risk for becoming sensitized [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/2\">",
"     2",
"    </a>",
"    ]. Therefore, dietary interventions instituted during pregnancy, lactation, and the first year of life have been proposed.",
"   </p>",
"   <p>",
"    The available literature concerning manipulation of a woman's diet in pregnancy or lactation (or both) in an attempt to achieve primary prevention of allergic disease will be reviewed here. The impact of breastfeeding on the development of allergic disease and general issues related to food allergen avoidance are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"     \"The impact of breastfeeding on the development of allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The suggestions made in this review do not apply to infants who manifest signs of allergic disease shortly after birth, as dietary interventions during lactation may then represent treatment, rather than primary prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be argued that all families should practice primary allergy prevention. However, this is sufficiently onerous that it is typically recommended only for those mothers whose children are most likely to develop allergy, or those infants at \"high-risk\" for developing allergic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     High-risk infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant's risk for developing allergic disease is based upon the family's atopic history. An infant is defined as a \"high-risk\" if there is at least one first degree relative (parent or sibling) with documented allergic disease. This definition is based upon a consensus among several committees representing the American Academy of Pediatrics (AAP), the joint guidelines of the European Society for Pediatric Allergology and Clinical Immunology (ESPACI), and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This definition of high-risk is relatively inclusive. As an example, an infant may be at high-risk because the father has allergic rhinitis or because multiple siblings have severe asthma and life-threatening food allergy. These two circumstances are clearly not equivalent. The general nature of this definition ensures that the findings of studies can be applied to significant portions of the general population, although it also introduces some uncertainty about how such findings should be applied to specific individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MATERNAL AVOIDANCE DIETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus can make immunologic responses to foods and other allergens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/2\">",
"     2",
"    </a>",
"    ]. It is currently unclear if these responses represent normal immunologic phenomena, are related to the subsequent development of allergy, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Study limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;These studies are difficult to perform and have been attempted with varying degrees of experimental rigor. Such study designs often include variables that are difficult to separate or control for, such as length of breastfeeding, use of supplemental formulas, and the introduction of solid foods to infants. In addition, the studies included in this review were performed at different times over the span of several decades (during which the prevalence of atopy has been changing) and on different populations, each with unique dietary and environmental influences.",
"   </p>",
"   <p>",
"    The lack of protective effect in some studies may also be due, in part, to reverse causation affecting the variables that were not controlled for in a given study. Specifically, when not requested to do so, mothers who believed their infants were at higher risk for atopic disorders might have been more likely to avoid certain foods in their diet, or to breastfeed and breastfeed longer, or mothers who were going to",
"    <span class=\"nowrap\">",
"     feed/supplement",
"    </span>",
"    with formula might have been more likely to choose a hypoallergenic formula.",
"   </p>",
"   <p>",
"    For each question discussed in this topic review, there are studies showing opposing results; however, the best studies and the majority of publications support the conclusion that maternal avoidance diets are not effective in preventing allergic disease in high risk infants and children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     During pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies attempting to prevent cow's milk (CM) and egg allergies by maternal CM and egg avoidance during late pregnancy have failed to show a reduction in food allergy, any other atopic disorder, or sensitization from birth through age five years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest trial, 212 pregnant women were randomly assigned to a diet free of CM and egg, or to a normal control diet from week 28 of gestation until delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/5\">",
"       5",
"      </a>",
"      ]. Many of the women on the exclusion diet also chose to avoid these foods during lactation. At ages 18 months and 5 years, there were no differences in the prevalence of AD, AR, or asthma in the two groups of infants born of these mothers [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/5,7\">",
"       5,7",
"      </a>",
"      ]. In contrast, at five years of age, egg allergy was significantly more common in the children of the mothers receiving the restricted diets [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/6\">",
"       6",
"      </a>",
"      ]. Additionally, maternal weight gain during pregnancy was negatively affected by these dietary restrictions.",
"     </li>",
"     <li>",
"      A review of the literature stated that there is no conclusive evidence for a protective effect of a maternal exclusion diet during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, both the AAP and European guidelines do not recommend maternal avoidance diets that exclude essential foods during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     During lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested for many years that the presence of food antigens in breast milk might sensitize nursing infants. Results of studies examining this hypothesis have been contradictory, and the cumulative data are not sufficient to support recommending food avoidance to breastfeeding mothers as a means of preventing allergy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective study of high-risk families encouraged exclusive breastfeeding for the first three months of life and delayed introduction of solid foods. In addition, one group of mothers avoided CM and egg in the last trimester of pregnancy and during the period of exclusive breastfeeding, a second group avoided CM and egg only during lactation, and a third group had no dietary restrictions. The period prevalences of AD, as well as the rates of specific sensitization to CM and egg at 6 and 12 months, were not significantly different between groups [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A longer-term study compared two groups of high-risk infants, both of which were breastfed and supplemented with protein hydrolysate formulas when necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/10\">",
"       10",
"      </a>",
"      ]. The study group was composed of infants whose mothers avoided egg, CM, and fish during the first three months of lactation, and the control group was composed of infants whose mothers had no dietary restrictions. Infants of mothers with restricted diets had less AD than the control group infants, although all other atopic manifestations were similar. However, in a 10-year follow-up study, there was no difference in the prevalence of allergic disease in these two groups of children [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Finally, one study found that maternal exclusion diet of egg, CM, fish, and nuts during lactation actually increased the presence of eczema and allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     During pregnancy and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found a favorable effect of maternal avoidance of CM during both late pregnancy and lactation in small numbers of subjects (12 to 14 mothers per group) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/13\">",
"     13",
"    </a>",
"    ]. Atopic mothers were randomly assigned to an avoidance diet or an unrestricted diet, and compared to non-atopic mothers on unrestricted diets. The avoidance diet resulted in a significantly reduced incidence of allergy in infants of atopic mothers at 12 and 18 months of life, although infants of non-atopic mothers had even lower rates of allergy.",
"   </p>",
"   <p>",
"    Finally, the prescription of food avoidance diets to women with high-risk infants during pregnancy or lactation (or both) was analyzed in a 2012 systematic review that identified five randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/5,13-16\">",
"     5,13-16",
"    </a>",
"    ], including over 900 patients, and concluded that there was insufficient evidence to advise women to avoid certain foods during pregnancy or lactation for the purpose of preventing allergic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Avoidance of peanut specifically",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous guidelines from the AAP suggested that avoidance of peanuts during pregnancy and lactation be considered for mothers with infants at high-risk for allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/2\">",
"     2",
"    </a>",
"    ]. Peanut differs from CM and egg in that peanut is not an essential food, avoidance will not usually lead to nutritional problems (unless possibly if the mother is a strict vegetarian and relies on peanut as a major protein and fat source), and peanut allergy is usually a lifelong condition. The findings of studies of maternal peanut avoidance, however, are again inconsistent.",
"   </p>",
"   <p>",
"    Studies that support an association between a mother&rsquo;s peanut ingestion during pregnancy and the atopic status of her child include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small, retrospective study in which mothers of young children with and without peanut sensitization (25 and 18 children, respectively) were questioned about dietary practices during pregnancy and lactation, showed that the consumption of peanut more than once a week during pregnancy, compared to less than once a week, increased the likelihood of having a peanut-sensitized child (OR=4, 98 percent CI ,0.73-24) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/18\">",
"       18",
"      </a>",
"      ]. No food challenges were performed to distinguish true peanut allergy from sensitization.",
"     </li>",
"     <li>",
"      A relatively large observational cohort study in which 503 infants, aged 3 to 15 months with evidence of cow&rsquo;s milk or egg allergy (ie, at high risk for food allergy) but without known peanut allergy, and their mothers were evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/19\">",
"       19",
"      </a>",
"      ]. Because of these selection criteria, these infants were not representative of the general population. Mothers were questioned about peanut intake during pregnancy, and the infants&rsquo; serum levels of peanut-specific IgE were determined, although challenges were not performed to determine if the children had clinical allergy. Maternal ingestion of peanut more than twice per week was associated with an increased risk of having peanut-specific IgE &ge;5",
"      <span class=\"nowrap\">",
"       kUA/L,",
"      </span>",
"      a level considered likely indicative of peanut allergy (OR=2.9, 95 percent CI, 1.7 to 4.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies that did",
"    <strong>",
"     not",
"    </strong>",
"    find an association between a mother&rsquo;s peanut ingestion and the atopic status of her child include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A much larger and more rigorous study of approximately 14,000 preschool children demonstrated no association with maternal consumption of peanuts during pregnancy and subsequent peanut allergy in the children. Mothers were retrospectively interviewed, however data on the cohort subjects were collected prospectively, and peanut allergy was confirmed by a clear history of an allergic reaction to peanut and by food challenges in some subjects. [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/20\">",
"       20",
"      </a>",
"      ]. In this protocol, cord blood was collected from all infants, and peanut-specific IgE could not be detected in cord blood of peanut-allergic individuals, arguing against the occurrence of peanut sensitization in utero. The same group also showed that the mothers of peanut-allergic children did not eat significantly more peanuts during breastfeeding than mothers of children in the control groups, which argued against the hypothesis that sensitization occurs by transmission of peanut allergens in breast milk.",
"     </li>",
"     <li>",
"      Two studies measured the impact of the 1998 United Kingdom (UK) government precautionary advice (which suggested atopic pregnant and breastfeeding mothers avoid peanut) on the prevalence of peanut sensitization and allergy. In one, while 61 percent of 957 mothers recalled hearing this advice in 1998, only 3.8 and 5 percent followed it during pregnancy and lactation, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/21\">",
"       21",
"      </a>",
"      ]. The prevalence of peanut sensitization in the children of these mothers was 2.8 percent, and 1.8 percent had peanut allergy, the highest prevalence for peanut allergy recorded to date in the UK. In the other study, half of more than 800 mothers modified their diet during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/22\">",
"       22",
"      </a>",
"      ]. However, of the children who did become sensitized to peanut, 77 percent of their mothers had avoided peanut during pregnancy. Thus, in these two studies, peanut avoidance during pregnancy and lactation did not appear to reduce the prevalence of peanut sensitization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      allergy.",
"     </li>",
"     <li>",
"      In a population-based Tasmanian birth cohort study, where a subgroup were available for analysis at 16 years of age, maternal ingestion of peanut during pregnancy was not associated with peanut sensitization at age 16 years. However, additional subgroup analysis revealed that maternal ingestion of peanut during pregnancy decreased the risk of peanut sensitization (and rye pollen sensitization) if there was no family history of asthma, and increased the risk of rye sensitization (peanut sensitization was increased but not significantly) if there was a family history of asthma. However, the sensitization to peanut and rye were likely explained by IgE binding to clinically irrelevant cross-reacting carbohydrates common to peanut and rye pollen, and no data were reported for clinical peanut allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2007 study suggested that the development of atopic sensitization to peanut occurs postnatally rather than in utero. T-cell cytokine responses and antibody assays of peanut-specific IgE and IgG4 were investigated in a cohort of 200 high-risk infants at birth (cord blood) and at 6, 12, and 24 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/24\">",
"     24",
"    </a>",
"    ]. Skin prick testing was also performed, although food challenges were not done and data on parental peanut ingestion was not collected. No association was found between cord blood T-cell reactivity and the subsequent postnatal IgE or skin test responses to peanut (presence or absence of peanut sensitization), whereas an increasingly strong association developed between these parameters beyond six months of age.",
"   </p>",
"   <p>",
"    Thus, the current data are not convincing enough to support the concept that maternal avoidance of peanut during pregnancy and lactation is an effective means of preventing the development of peanut allergy in the general population. However, because the data are inconclusive, we believe it is reasonable for a woman who already has a child with food allergy to consider peanut avoidance during a future pregnancy and possibly lactation, since there is at least one study that found an association, and peanut is not an essential food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF PEDIATRIC GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 report sponsored by the American Academy of Pediatrics concluded that there was insufficient evidence to recommend that a woman whose child is at high-risk for allergic disease (defined as having at least one parent or sibling with documented allergic disease) avoid allergenic foods during pregnancy or lactation for the purpose of preventing allergic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/25\">",
"     25",
"    </a>",
"    ]. This report was based upon the conclusion that, although such interventions may reduce AD in early life, evidence for a long-term effect were lacking. Several European pediatric societies have drawn similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MATERNAL AVOIDANCE DIETS AS PART OF INTENSIVE ALLERGEN AVOIDANCE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of studies have examined maternal avoidance diets in combination with other allergen avoidance measures, with more promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intensive series of interventions was studied in a randomized trial of 165 high-risk mother-child pairs [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/26\">",
"       26",
"      </a>",
"      ]. Interventions included maternal avoidance of CM, egg, and peanut during the third trimester and lactation, combined with infant avoidance of CM until age one year, egg until age two years, and peanut and fish until age three years. In infants aged zero to two years, there was a significant reduction in food allergy and milk sensitization in the prophylactic-treated group compared to the control group. Food allergy frequently resolves between the ages of two and seven years, and resolution was seen in this study as well. By the age of seven years, food allergy occurred to a similar extent in prophylactic-treated and control groups. In addition, the cumulative prevalences of AD, AR, asthma, and any allergic disorder were similar in the groups at seven years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link\">",
"       \"The natural history of childhood food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another study extended allergen avoidance further by examining the effect of simultaneous avoidance of both food and environmental allergens. In this trial, 120 infants were identified prenatally or at birth as being at \"very high-risk\" for allergic disease, as defined by having two first-degree relatives with allergic disease, or having elevated cord blood levels of IgE and one first-degree relative with allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/27\">",
"       27",
"      </a>",
"      ]. The intervention group of 58 infants was either breastfed by mothers avoiding dairy, egg, nuts, fish, and soya, or fed with extensively hydrolyzed formula. The diet in pregnancy was not altered. Infants were also not given these five allergenic foods, nor were they given wheat, until after 12 months of age. In addition, the infants' homes were treated with acaricide and their cot mattresses encased with polyvinyl covers to reduce dust mite exposure. Maternal compliance with the diet was assessed by measuring CM proteins in breast milk. Children were followed prospectively from birth and assessed at the ages of one, two, four, and eight years for sensitization to food and environmental allergens, and the development of atopic disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study was unique in combining food and environmental allergen avoidance, and in monitoring maternal compliance. Sensitization to food allergens was more common in the control group at age eight, although the difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20119/abstract/27\">",
"     27",
"    </a>",
"    ]. The prevalence of clinically apparent food allergy was reduced by 50 percent in the intervention children, although the numbers were small and the effect did not reach statistical significance. In contrast, there were significantly lower rates of AD, AR, and persistent asthma in the intervention group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal avoidance diets in pregnancy and lactation, combined with delayed introduction of allergenic foods, did not reduce allergic disease in high-risk children. However, potential benefit was demonstrated when even more intensive allergen avoidance was studied in a group of highly motivated mothers with infants at \"very high-risk\" for allergy. Avoidance of multiple allergenic foods in lactation and early infancy, combined with rigorous dust mite avoidance measures, did show some benefit. The effects were greater for the prevention of AD and respiratory allergy, and less dramatic for the prevention of food allergy. Further studies are required in these specific populations before recommendations can be made.",
"   </p>",
"   <p>",
"    In our specialty clinic, we encounter highly-motivated parents of severely allergic children, who are interested in attempting combinations of early interventions to improve the chances that future offspring will be less affected by allergic disease. There is minimal evidence that these primary prevention strategies are harmful, provided the pregnant woman's nutrition is adequate. In some cases, the family has already adopted a diet free of certain food allergens that other siblings must avoid and little additional effort is needed. In such circumstances, we discuss the limitations of the currently available information with the patient and determine management on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention for allergic disease involves interventions designed to block immunologic sensitization to an allergen(s). The following suggestions do NOT apply to infants who manifest signs of allergic disease shortly after birth, as dietary interventions during lactation may then represent treatment, rather than primary prevention. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal avoidance of allergenic foods during pregnancy and lactation has been studied in women whose children are at \"high-risk\" for developing allergic disease. A \"high-risk\" infant is one with at least one first-degree relative (sibling or parent) with documented allergic disease (ie, atopic dermatitis, allergic asthma, allergic rhinitis, or food allergy). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal avoidance of allergenic foods during pregnancy and lactation, as an isolated intervention, has not proven effective in preventing persistent allergic disease in children. Some studies show a reduction in infantile atopic dermatitis, although this benefit is no longer apparent by school age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Maternal avoidance diets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some pregnant women may already be avoiding allergenic foods because of food allergy in other children in the household. In these cases, we typically advise them to continue their current diets, and we offer dietary counseling to ensure adequate maternal nutrition.",
"     </li>",
"     <li>",
"      We suggest that women not change their diets to avoid essential foods (such as cow's milk or egg) during pregnancy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There is inadequate evidence that this intervention prevents allergic disease and it may compromise maternal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal nutrition. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'During pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that women not change their diets to avoid essential foods (such as cow's milk and egg) during lactation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There is poor evidence for a long-term protective effect against allergic disease, although there may be an",
"      <span class=\"nowrap\">",
"       early/transient",
"      </span>",
"      effect on reducing atopic dermatitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      food allergy. Women who are motivated by these uncertain benefits and wish to avoid certain foods may do so, provided attention is paid to nutrition. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'During pregnancy and lactation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest that women eliminate peanuts from their diet during pregnancy and lactation as a means of preventing peanut allergy in their offspring (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, women who wish to avoid peanut may do so without concerns about nutrition, since peanut is not an essential part of most people's diet. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Avoidance of peanut specifically'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies have demonstrated that maternal dietary interventions in pregnancy and lactation, in isolation, are not sufficient to significantly reduce the incidence of allergic disease in offspring. However, these interventions may be useful in combination with other allergen avoidance measures in early life; further studies are needed to determine this.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/1\">",
"      Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003; 111:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/2\">",
"      Zeiger RS. Food allergen avoidance in the prevention of food allergy in infants and children. Pediatrics 2003; 111:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/3\">",
"      American Academy of Pediatrics. Committee on Nutrition. Hypoallergenic infant formulas. Pediatrics 2000; 106:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/4\">",
"      H&oslash;st A, Koletzko B, Dreborg S, et al. Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Arch Dis Child 1999; 81:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/5\">",
"      F&auml;lth-Magnusson K, Kjellman NI. Development of atopic disease in babies whose mothers were receiving exclusion diet during pregnancy--a randomized study. J Allergy Clin Immunol 1987; 80:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/6\">",
"      F&auml;lth-Magnusson K, Kjellman NI. Allergy prevention by maternal elimination diet during late pregnancy--a 5-year follow-up of a randomized study. J Allergy Clin Immunol 1992; 89:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/7\">",
"      Lilja G, Dannaeus A, Foucard T, et al. Effects of maternal diet during late pregnancy and lactation on the development of atopic diseases in infants up to 18 months of age--in-vivo results. Clin Exp Allergy 1989; 19:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/8\">",
"      Muraro A, Dreborg S, Halken S, et al. Dietary prevention of allergic diseases in infants and small children. Part III: Critical review of published peer-reviewed observational and interventional studies and final recommendations. Pediatr Allergy Immunol 2004; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/9\">",
"      Herrmann ME, Dannemann A, Gr&uuml;ters A, et al. Prospective study of the atopy preventive effect of maternal avoidance of milk and eggs during pregnancy and lactation. Eur J Pediatr 1996; 155:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/10\">",
"      Sigurs N, Hattevig G, Kjellman B. Maternal avoidance of eggs, cow's milk, and fish during lactation: effect on allergic manifestations, skin-prick tests, and specific IgE antibodies in children at age 4 years. Pediatrics 1992; 89:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/11\">",
"      Hattevig G, Sigurs N, Kjellman B. Effects of maternal dietary avoidance during lactation on allergy in children at 10 years of age. Acta Paediatr 1999; 88:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/12\">",
"      Pollard C, Phil M, Bevin S. Influence of maternal diet during lactation upon allergic manifestations in infants: tolerization or sensitization. J Allergy Clin Immunol 1996; 97:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/13\">",
"      Lovegrove JA, Hampton SM, Morgan JB. The immunological and long-term atopic outcome of infants born to women following a milk-free diet during late pregnancy and lactation: a pilot study. Br J Nutr 1994; 71:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/14\">",
"      Pali-Sch&ouml;ll I, Renz H, Jensen-Jarolim E. Update on allergies in pregnancy, lactation, and early childhood. J Allergy Clin Immunol 2009; 123:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/15\">",
"      Lilja G, Dannaeus A, F&auml;lth-Magnusson K, et al. Immune response of the atopic woman and foetus: effects of high- and low-dose food allergen intake during late pregnancy. Clin Allergy 1988; 18:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/16\">",
"      Cant AJ, Bailes JA, Marsden RA, Hewitt D. Effect of maternal dietary exclusion on breast fed infants with eczema: two controlled studies. Br Med J (Clin Res Ed) 1986; 293:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/17\">",
"      Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Cochrane Database Syst Rev 2012; 9:CD000133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/18\">",
"      Frank L, Marian A, Visser M, et al. Exposure to peanuts in utero and in infancy and the development of sensitization to peanut allergens in young children. Pediatr Allergy Immunol 1999; 10:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/19\">",
"      Sicherer SH, Wood RA, Stablein D, et al. Maternal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants. J Allergy Clin Immunol 2010; 126:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/20\">",
"      Lack G, Fox D, Northstone K, et al. Factors associated with the development of peanut allergy in childhood. N Engl J Med 2003; 348:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/21\">",
"      Hourihane JO, Aiken R, Briggs R, et al. The impact of government advice to pregnant mothers regarding peanut avoidance on the prevalence of peanut allergy in United Kingdom children at school entry. J Allergy Clin Immunol 2007; 119:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/22\">",
"      Dean T, Venter C, Pereira B, et al. Government advice on peanut avoidance during pregnancy--is it followed correctly and what is the impact on sensitization? J Hum Nutr Diet 2007; 20:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/23\">",
"      Kemp AS, Ponsonby AL, Dwyer T, et al. Maternal antenatal peanut consumption and peanut and rye sensitization in the offspring at adolescence. Clin Exp Allergy 2011; 41:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/24\">",
"      Rowe J, Kusel M, Holt BJ, et al. Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohort. J Allergy Clin Immunol 2007; 119:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/25\">",
"      Greer FR, Sicherer SH, Burks AW, et al. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008; 121:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/26\">",
"      Zeiger RS, Heller S. The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol 1995; 95:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20119/abstract/27\">",
"      Arshad SH, Bateman B, Sadeghnejad A, et al. Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. J Allergy Clin Immunol 2007; 119:307.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2404 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-CC27B9A4A4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20119=[""].join("\n");
var outline_f19_41_20119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      High-risk infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MATERNAL AVOIDANCE DIETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Study limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      During pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      During lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      During pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Avoidance of peanut specifically",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RECOMMENDATIONS OF PEDIATRIC GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MATERNAL AVOIDANCE DIETS AS PART OF INTENSIVE ALLERGEN AVOIDANCE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=related_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20120="Primary care of gay men";
var content_f19_41_20120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary care of gay men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20120/contributors\">",
"     Harvey J Makadon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20120/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20120/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/41/20120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the care of gay men reflects standards of recommended care of all men (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there are unique features regarding both medical and behavioral health of gay men of importance to practicing clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, gay men may have particular concerns about access to care, insurance coverage, and the clinical office environment that should be considered as part of ensuring equal access to care [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthy People 2020, a document that outlines health goals for the current decade in the United States (US), highlighted areas of concern regarding health care disparities impacting gay men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/5\">",
"     5",
"    </a>",
"    ]. In particular, gay men are at higher risk of human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), especially among communities of color. In addition, gay men across a large age spectrum are more likely to attempt suicide, be homeless, and have high rates of tobacco, alcohol, and other drug use. Older gay men face additional barriers to health because of isolation and lack of supportive services.",
"   </p>",
"   <p>",
"    Despite identified disparities, education about the care of gay men is sorely lacking in the context of medical education [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY AND IDENTITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The population that has come to be referred to as \"gay\" in the West is not a descriptive term that would be recognized by all men who have sex with men (MSM). While gay culture is increasingly open and discussed, the world of MSM consists of a diverse population that often may respond differently depending on how communications in clinical settings are framed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the terms \"MSM\" and \"gay\" do not describe exactly the same group of men. \"Gay\" is generally used to describe a sexual orientation, while \"MSM\" describes a behavior. Additionally, some who are just beginning to come out may experience desire to be intimate with other men, but may not yet have been sexually active with men or even identify as being gay.",
"   </p>",
"   <p>",
"    Some MSM will not relate to the term \"gay\" or homosexual, and do not regard sex with other men as sexual activity, a term they reserve for sexual relations with women. This is particularly true among individuals from non-Western cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/9\">",
"     9",
"    </a>",
"    ]. Nevertheless, it is also common in the US. Terms such as MSM or &ldquo;same gender loving&rdquo; are often used in place of the word gay. Several years ago a term &ldquo;on the down low&rdquo; was used in the African American community [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/10\">",
"     10",
"    </a>",
"    ], but unless someone uses this term to describe themselves, it is not recommended.",
"   </p>",
"   <p>",
"    Some men may not identify themselves as belonging to the identity of their biological sex, and instead see themselves as individuals of the opposite sex. These are members of the transgender or transsexual community. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=see_link\">",
"     \"Transsexualism: Epidemiology, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues are important for health care, because issues related to sexual desire, sexual activity, and sexual identity may lead to distinct psychological concerns and may affect risks for sexually transmitted diseases and certain cancers. Understanding a patient's sexual orientation, behavior, and identity all have a bearing on the ability to provide quality care.",
"   </p>",
"   <p>",
"    It is also important to recognize that gay men are an extremely diverse group with respect to race, ethnicity, and socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kinsey's study Sexual Behavior in the Human Male in 1948 was the first report on homosexual experiences among men in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/12\">",
"     12",
"    </a>",
"    ]. While questions have been raised about sampling bias, he found that 37 percent of men had some homosexual experience to the point of orgasm and that 10 percent of men reported that they were predominantly homosexual for at least three years between the ages of 16 and 55. Four percent of white males interviewed reported being exclusively homosexual from the time of adolescence. He devised a scale to measure sexual orientation and suggested that there was a spectrum of the extent to which an individual engaged in male to male sexual relations at different points in his life. The implications of this for adolescent sexuality are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=see_link\">",
"     \"Adolescent sexuality\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been a number of studies since Kinsey. One of the most highly regarded correctly recognized that homosexuality should be considered to include behavior and desire as well as identity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/13\">",
"     13",
"    </a>",
"    ]. Using these criteria the study found that 9 percent of men reported having engaged in at least one same-gender sexual activity since puberty. Given the identity category choices of heterosexual, homosexual, bisexual, or something else, 2.8 percent of men surveyed reported \"some level of homosexual identity\". Recent critiques of these studies have suggested that because of their dependence on self identification, they may have undercounted the true prevalence of men with a history of same sex behavior",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    desire.",
"   </p>",
"   <p>",
"    Regardless of the precise numbers, in the US the most recent census figures confirm that \"same sex\" households are widespread through the country. Such households were found in over 99 percent of counties in every state [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, all clinicians, at least in the US, should be considering \"gay\" or MSM sexual behavior when seeing patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OBTAINING A HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is common in US medical schools to be taught, when taking a sexual history, to ask whether someone is sexually active, and if so, whether he has sex with men, women, or both? Patients should be told that the information related to sexual orientation is asked of everyone, and has relevance to health care and prevention decisions.",
"   </p>",
"   <p>",
"    Although nonjudgmental questions about sexual behavior are valuable, they may not identify those who have never engaged in same sex behavior but have the desire to do so. Unrealized sexual desires may be an important trigger for discussing issues such as related anxiety or depression, fear of \"coming out,\" and concern about how this information in the medical record could affect potential insurance coverage or employment.",
"   </p>",
"   <p>",
"    Additional questioning about concerns with sexuality or gender identity may help identify issues related to sexual health and concern about sexual function, as well as possible gender identity issues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=see_link\">",
"     \"Transsexualism: Epidemiology, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such questioning may include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Are you sexually attracted to men, women, or both?\"",
"     </li>",
"     <li>",
"      \"Do you feel comfortable with your sexuality?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is also important to ask about any history of sexually transmitted infections including exposure to HIV. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'HIV'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ISSUES TO TARGET",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few population based studies of health issues in gay men. Based on clinical experience and epidemiology, we identify a number of areas in which clinicians providing primary care to gay men should provide additional emphasis beyond what they might focus on in heterosexual men. We agree with a monograph published as a companion document to the US Surgeon General's report Healthy People 2010 by the Gay and Lesbian Medical Association that important issues to target include: cancer;",
"    <span class=\"nowrap\">",
"     HIV/AIDS;",
"    </span>",
"    immunizations and infectious diseases including sexually transmitted diseases, substance and tobacco abuse, behavioral health and mental disorders, and domestic violence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gay men experience increased rates of anal carcinoma. Anal carcinoma is more common in HIV infected men, but it has also been found in those without HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12761?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification and epidemiology of anal cancer\", section on 'Sexual activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12761?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification and epidemiology of anal cancer\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The putative cause is infection with human papilloma virus (HPV) which appears to progress through stages of anal dysplasia to anal carcinoma in much the same way as cervical HPV infection progresses to cervical carcinoma in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/16\">",
"     16",
"    </a>",
"    ]. Certain subtypes of HPV appear to predispose more to this progression. A 2012 systematic review showed that there is a higher prevalence of anal HPV infection in MSM, regardless of HIV status [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Screening for anal cancer with anal Pap smears is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], but at least one study has suggested that such screening is cost effective, at least in HIV infected men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/20\">",
"     20",
"    </a>",
"    ]. We suggest discussing with MSM that anal Pap smears are used to evaluate the anal transition zone for anal squamous intraepithelial lesions; however, evidence on screening outcomes is lacking. This issue is discussed in detail separately along with a description of how to perform an anal Pap smear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV is also associated with oropharyngeal cancer (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    ). No special screening beyond that which occurs with routine medical exams and dental care is recommended at this time.",
"   </p>",
"   <p>",
"    HPV vaccine has been recommended for boys and young men to prevent HPV and anal cancer. Use of the HPV vaccine in MSM is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H17#H17\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Efficacy and immunogenicity in males'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H221828025\">",
"    <span class=\"h2\">",
"     Sexually transmitted diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians can play an important role in prevention of sexually transmitted diseases (STDs) by discussing risk reduction and safe sexual practices with patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/21\">",
"     21",
"    </a>",
"    ]. Individuals need reassurance that close physical contact, kissing, and hugging are safe. While there is risk of HIV transmission associated with oral sex, STDs are largely transmitted during vaginal or anal intercourse or when sharing needles during IV drug use. Clinicians should spend more time on such discussions when there is a concern that a patient may have multiple sexual partners, has not been practicing safe sex, has been recently diagnosed with an STD, or engages in drug abuse. MSM should be offered screening tests for HIV, syphilis, chlamydia, and gonorrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link&amp;anchor=H19#H19\">",
"     \"Screening for sexually transmitted infections\", section on 'Men who have sex with men'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Health departments of major US cities have reported increased incidences of STDs in the past several years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. It is felt that this rise has been fueled in part by concomitant use of drugs at circuit parties and clubs as discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Drug abuse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of cases of HIV overall in the US has been stable, but HIV incidence has increased in populations of MSM, particularly African-American and Hispanic adolescents and young men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/24\">",
"     24",
"    </a>",
"    ]. The incidence of HIV among African American MSM has increased 48 percent from 2006 to 2009, and 64 percent of new cases of HIV in 2009 were among MSM who also use intravenous drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/24\">",
"     24",
"    </a>",
"    ]. It is particularly important to address HIV risk and counsel patients with known HIV infection. The US Centers for Disease Control (CDC) recommends that all HIV infected patients be counseled that the only way to prevent sexual transmission of HIV to uninfected people is through abstinence or by only having sex with people already known to be infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/25\">",
"     25",
"    </a>",
"    ]. Even restricting sex to others with known HIV infection has the potential risk for both partners of superinfection with other strains of HIV if condoms are not used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link&amp;anchor=H30#H30\">",
"     \"Immunology of HIV-1 infection\", section on 'HIV superinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the potential risk to noninfected individuals, it is important to counsel for use of condoms whenever there is vaginal or anal intercourse. It is also important to discuss that there is a risk of transmission with oral sex, and this is likely highest when an HIV infected man ejaculates into the mouth of someone who has open mouth sores. While it makes sense to inform patients that routine use of condoms can decrease the risk of HIV transmission with oral sex, it is also important to recognize that many patients will not wish to use condoms for oral sex when there are no factors increasing the risk of transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=see_link&amp;anchor=H9053137#H9053137\">",
"     \"Nonoccupational exposure to HIV in adults\", section on 'Risk of transmission of HIV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the US, where more than 250,000 people in 2003 were estimated to be unaware that they were infected with HIV, the CDC recommends that HIV screening be routinely performed in most care settings on all adolescents and adults unless they specifically \"opt out\" of such testing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/26\">",
"     26",
"    </a>",
"    ]. Individual state laws have changed dramatically to allow routine HIV testing, but a few states have not yet allowed this. Particular populations may be at particular risk; data from the CDC suggest an almost 49 percent increase in the incidence of HIV among young black MSM between 2006 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in settings and countries where HIV screening is not universally recommended, all MSM should be offered HIV testing; individuals should not be tested without being informed of the test and allowed to refuse testing. We suggest annual testing for MSM, and more frequent testing for MSM engaging in high-risk behaviors, such as unprotected sex with men known or likely to be infected with HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MSM should be educated about getting postexposure prophylaxis in the event of an unsafe sexual encounter (eg, condom breakage). Repeated exposures suggest the need for additional counseling about risk reduction and safer sex. Pre-exposure prophylaxis for HIV has been shown to be effective and appears to be safe in MSM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link&amp;anchor=H7740706#H7740706\">",
"     \"Pre-exposure prophylaxis against HIV infection\", section on 'Clinical data in men who have sex with men'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H221828315\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC also recommends screening asymptomatic sexually active gay men for syphilis, chlamydia, and gonorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Although there are few data to show that these screening tests improve outcomes, it is reasonable to perform screening on at least an annual basis given the high prevalence rates of these STDs in MSM. Routine testing for HPV infection is not recommended until more data are available on the reliability of screening methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=see_link&amp;anchor=H152757#H152757\">",
"     \"Screening for Chlamydia trachomatis\", section on 'Men who have sex with men'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link\">",
"     \"Diagnosis of gonococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to routine adult immunizations, we recommend that MSM who are sexually active receive the additional vaccines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis A and B vaccines in light of the sexual transmission of both of these viruses [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=see_link\">",
"       \"Approach to immunizations in healthy adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"       \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the fall of 2012, an outbreak of invasive meningococcal meningitis was detected in MSM in New York City. Some states in the US have recommended meningococcal vaccination to prevent infection in MSM (particularly if HIV-infected) who have had contact with MSM from New York City. [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/31,32\">",
"       31,32",
"      </a>",
"      ](See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=see_link\">",
"       \"Meningococcal vaccines\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H19#H19\">",
"       \"Immunizations in HIV-infected patients\", section on 'Meningococcal vaccine'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HPV vaccine has been approved for boys and young men to prevent anal cancer. Use of the HPV vaccine in MSM is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H17#H17\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Efficacy and immunogenicity in males'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Substance and tobacco abuse",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Tobacco abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking is more common among gay men than in heterosexual men in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/33\">",
"     33",
"    </a>",
"    ]. Younger gay men are smoking more now than ever. Clinicians can counsel and assist with smoking cessation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Alcohol use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholism is more prevalent among gay men in the US than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/34\">",
"     34",
"    </a>",
"    ], and has been thought to contribute to some of the disinhibition that leads to riskier sexual behavior and exposure to HIV. Clinicians can often be the ones who first detect evidence of this problem through discussion. A multidisciplinary approach to stopping alcohol use is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Drug abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, drugs for abuse are not different among the gay populations than among others. There are, however, trends of drug use that do predominate in the gay community. These drugs are frequently used in clubs and at circuit parties (large events held in different communities at different times of the year). Depending on what drugs are being used, these may lead to significant short and long-term morbidity. The disinhibition associated with these has been one explanation for rising rates of HIV infection and STDs among gay men after years of decline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trends in drug use change over time. Several years ago commonly used drugs were MDMA (Ecstasy) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    (K). While these are still in use their popularity has been outstripped by an epidemic of methamphetamine hydrochloride use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/36\">",
"     36",
"    </a>",
"    ]. According to the 2003 National Survey on Drug Use and Health, 12.3 million Americans age 12 and older had tried methamphetamine at least once in their lifetimes (5.2 percent of the population), with the majority of past-year users between 18 and 34 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemically related to amphetamines, this variant, which can be produced in small local labs from common ingredients, has greater central nervous system (CNS) effects and a high potential for abuse and addiction. It can be taken orally or intranasally, smoked, or injected. The form that can be inhaled resembles crystals and is referred to as \"crystal meth\" or \"ice.&rdquo; It is a stimulant that can cause an immediate pleasurable rush, euphoria, and increased sexual desire. Methamphetamine has a number of significant deleterious short and long-term effects.",
"   </p>",
"   <p>",
"    In many gay clubs found throughout New York City and elsewhere, methamphetamine is often used in an injectable form, placing users and their partners at risk for transmission of HIV, hepatitis C, and other STDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Behavioral health and mental disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was only in 1973 that homosexuality was declassified as a mental disorder. In 1986, the term \"ego-dystonic homosexuality\" was removed from the Diagnostic and Statistical Manual of Mental Disorders (DSM-III). There have been no major studies of mental health issues in the gay and lesbian population. However, smaller studies have identified higher rates of major depressive disorders and bipolar disorders in gay men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/38\">",
"     38",
"    </a>",
"    ]. There also appears to be an increased prevalence of anxiety disorders particularly in relation to a man's growing consciousness of being gay and struggling to come out [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there has been debate about whether gay men are at higher risk for suicide, many studies show increased suicidal ideation and suicide attempts among gay men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/40\">",
"     40",
"    </a>",
"    ]. Rates are particularly high among gay youth; suicidal ideation and attempts are three to seven times higher among gay youth than among heterosexuals. Gay adolescents and men have also been found to have increased disorders of body image as well as eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of clear data from solid research, the environment in which many gay adolescents and adults grow up, the violence faced by many at times in their lives, and the anxiety and fear during the process of coming out can leave emotional scars that often need to be addressed during adolescent or adult life. As a result, discussion of these and related issues is important and referral for counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychopharmacological intervention is often warranted.",
"   </p>",
"   <p>",
"    Since the legalization of gay marriage in several states in the US, issues of family commitment, marriage, and adoption are emerging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Domestic violence, sexual assault, and hate crimes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest rates of domestic violence among intimate gay couples at approximately the same rate as among heterosexual couples [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two striking differences are that informal discussions with local victims suggest that there is little screening done for this among gay couples, and facilities designed to accommodate victims of domestic violence are rarely able to accommodate men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A related and significant issue is sexual assault among gay men in general which tend, due to the shame of the victim as well as bias among some law enforcement officers, to go underreported. Rape crisis programs are often unprepared to deal with male victims of sexual assault and rape and some legal definitions of rape exclude male victims. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On a broader scale, studies have shown that gay men are perhaps the most frequent victims of violence. Finding a sympathetic place to go can be difficult. One study showed that only a small percentage of violent incidents were reported due to fear that open discussion would lead to further injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/45\">",
"     45",
"    </a>",
"    ]. There is some justification for this belief in that an analysis of surveys of antigay violence showed a significant number of victims had been victimized by police [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary care clinicians in the US should be aware of the relatively high prevalence of violence and hate crimes against gay men in the community. Although, as with heterosexual domestic violence and violence in general, there is little evidence about the benefits of screening or intervention, we believe that it is important to discuss with patients whether they have ever been physically or emotionally assaulted so that appropriate interventions be designed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MAKING CARE ACCESSIBLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gay men, like all patients, must be made to feel welcome in order to increase the likelihood that they will be honest with their providers and follow advice for preventive care. Perhaps the most important feature of care is application of an open and nonjudgmental approach to finding out about each patient, supplemented by appropriate questions.",
"   </p>",
"   <p>",
"    The same applies to the office environment. Educational materials in waiting areas can give subtle signs that a practice may not be sensitive to same-sex issues if they do not include information on avoidance of STD's and HIV or the availability of resources for Domestic Violence.",
"   </p>",
"   <p>",
"    Similarly registration forms which ask for information in language that suggests only traditional family structures can be off-putting. It is important that rather than just asking if a patient is married, single, or divorced, there be an option to indicate a significant other or domestic partner. Similarly in countries and states where same sex marriages are recognized, staff must understand to treat this information in the same way they would treat information about spouses on forms submitted by heterosexual couples [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Facilities for children have to recognize that increasing numbers of children will now register with two same sex parents. Clinicians must be culturally sensitive to insure that all of our patients do not experience psychological barriers to care.",
"   </p>",
"   <p>",
"    The Joint Commission and Department of Health and Human Services in the US are looking at ways to improve the care environment for gay men and to collect more data routinely in clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20120/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While much of the care of gay men reflects standard of recommended care of all men, there are unique features regarding both medical and behavioral health of gay men of importance to practicing clinicians. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"       \"Overview of preventive medicine in adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many men who have sex with men don&rsquo;t identify as gay. In light of this, it is important to ask patients about identity as well as behavior and desire. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Obtaining a history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that clinicians ask the following nonjudgmental questions of adult patients to determine both sexual activities and sexual desires (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Obtaining a history'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"Have you been sexually active in the past year?\"",
"     </li>",
"     <li>",
"      \"Do you have sex with women, men, or both?\"",
"     </li>",
"     <li>",
"      \"Are you sexually attracted to men, women, or both?\"",
"     </li>",
"     <li>",
"      \"Do you feel comfortable with your sexuality?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest at least annual screening for HIV, syphilis, chlamydia, and gonorrhea in men who have sex with men (MSM) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). More frequent testing may be indicated in MSM engaging in high-risk behaviors such as unprotected sex with men known or likely to be infected with HIV. Additionally, MSM should be counseled about safer sex, risk reduction, and the availability of postexposure prophylaxis for sporadic exposures to HIV. (See",
"      <a class=\"local\" href=\"#H221828025\">",
"       'Sexually transmitted diseases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"       \"Screening for sexually transmitted infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of evidence on outcomes, we suggest performing screening with anal cytology for anal cancer in MSM who are infected with HIV (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) as well as those who have perianal HPV lesions. If abnormalities are found, recommend follow-up with high-resolution anoscopy. It is reasonable to discuss the risks and benefits of such screening with other MSM. Men with perianal warts should be carefully evaluated for dysplastic lesions as part of management of those warts. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all MSM be immunized for hepatitis A and hepatitis B (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Other immunizations may also be necessary. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Immunizations'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Other issues that are worth particular attention in the primary care of gay men include drug abuse, tobacco abuse, alcoholism, domestic and community violence, and behavioral health and mental disorders. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Issues to target'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary care providers should consider modifying aspects of their office environment so as to provide a care location that is perceived as welcoming by all patients including gay men. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Making care accessible'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/1\">",
"      Beck LH. Periodic health examination and screening tests in adults. Hosp Pract (Minneap) 1999; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/2\">",
"      Mayer KH, Bekker LG, Stall R, et al. Comprehensive clinical care for men who have sex with men: an integrated approach. Lancet 2012; 380:378.",
"     </a>",
"    </li>",
"    <li>",
"     Bradford, J, Honnold, J. Unpublished analysis of data from the National Lesbian Health Care Survey, 1994.",
"    </li>",
"    <li>",
"     Millman M. Access to Health Care in America, National Academy Press, Washington, DC 1993.",
"    </li>",
"    <li>",
"     file://healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=25 (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/6\">",
"      Makadon HJ. Improving health care for the lesbian and gay communities. N Engl J Med 2006; 354:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/7\">",
"      Kuehn BM. IOM: Data on health of lesbian, gay, bisexual, and transgender persons needed. JAMA 2011; 305:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/8\">",
"      Bonvicini KA, Perlin MJ. The same but different: clinician-patient communication with gay and lesbian patients. Patient Educ Couns 2003; 51:115.",
"     </a>",
"    </li>",
"    <li>",
"     Seabrook J. Love in a Different Climate: Men who have sex with men in India, Verso, 1999.",
"    </li>",
"    <li>",
"     King JL. On the Down Low: A Journey Into the Lives of \"Straight\" Black Men Who Sleep with Men, Broadway, 2004.",
"    </li>",
"    <li>",
"     Institute of Medicine. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. The National Academies Press, Washington, DC 2011. Available at: file://www.iom.edu/Reports/2011/The-Health-of-Lesbian-Gay-Bisexual-and-Transgender-People.aspx (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     Kinsey AC, Wardell BP, Martin CE. Sexual Behavior in the Human Male, Indiana University Press, Bloomington, IN 1998.",
"    </li>",
"    <li>",
"     Laumann O, Gagon JH, Michaels S. The Social Organization of Sexuality: Sexual Practices in the United States, University of Chicago Press, 1994.",
"    </li>",
"    <li>",
"     Census 2010 Data Shows Same-Sex Couples Identified as Spouses in Every State; First Revised Estimates of Same-Sex Couples for Cities and Counties. The Williams Institute 2011. Available at: file://williamsinstitute.law.ucla.edu/press/press-releases/census-2010-data-shows-same-sex-couples-identified-as-spouses-in-every-state-first-revised-estimates-of-same-sex-couples-for-cities-and-counties/ (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/15\">",
"      Dean, LI, Meyer, H, et al. Lesbian, Gay, Bisexual, and Transgender Health: Findings and Concerns. Journal of the Gay and Lesbian Medical Association 2000; 4:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/16\">",
"      Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994; 8:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/17\">",
"      Boehmer U, Cooley TP, Clark MA. Cancer and men who have sex with men: a systematic review. Lancet Oncol 2012; 13:e545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/18\">",
"      Anderson JS, Vajdic C, Grulich AE. Is screening for anal cancer warranted in homosexual men? Sex Health 2004; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/19\">",
"      Goldie SJ, Kuntz KM, Weinstein MC, et al. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med 2000; 108:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/20\">",
"      Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999; 281:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/21\">",
"      Kohn WG, Collins AS, Cleveland JL, et al. Guidelines for infection control in dental health-care settings--2003. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/22\">",
"      Klausner JD, Wong W. Sexually Transmitted Diseases in Men Who Have Sex with Men: A Clinical Review. Curr Infect Dis Rep 2003; 5:135.",
"     </a>",
"    </li>",
"    <li>",
"     Mayer, KH, Goldhammer, et al. STI trends among MSM at the largest health center caring for gay men in New England. Abstract P144. National STD Prevention Conference, Philadelphia, PA, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/24\">",
"      Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/25\">",
"      Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, et al. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis 2004; 38:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/26\">",
"      Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/27\">",
"      Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Screening and testing men who have sex with men (MSM) for syphilis. file://www.cdc.gov/std/see/MSM/SEE-MSM-HCP.pdf (Accessed on August 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/29\">",
"      Clover RD, Zimmerman RK, Advisory Committee on Immunization Practices. American Academy of Family Physicians. American College of Obstetricians and Gynecologists. American College of Physicians. American Society of Internal Medicine. Centers for Disease Control and Prevention. The 2003 Recommended Adult Immunization Schedule. Advisory Committee on Immunization Practices. American Academy of Family Physicians. American College of Obstetricians and Gynecologists. American College of Physicians. American Society of Internal Medicine. Centers for Disease Control and Prevention. Am Fam Physician 2002; 66:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/30\">",
"      Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     Commonwealth of Masschusetts Department of Public Health. Health Advisory: Meningococcal vaccine recommendations for men who have sex with men. October 25, 2012.",
"    </li>",
"    <li>",
"     www.cdc.gov/mmwr/preview/mmwrhtml/mm6151a4.htm?s_cid=mm6151a4_e (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/33\">",
"      Stall RD, Greenwood GL, Acree M, et al. Cigarette smoking among gay and bisexual men. Am J Public Health 1999; 89:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/34\">",
"      Koblin BA, Chesney MA, Husnik MJ, et al. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study. Am J Public Health 2003; 93:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/35\">",
"      Frosch D, Shoptaw S, Huber A, et al. Sexual HIV risk among gay and bisexual male methamphetamine abusers. J Subst Abuse Treat 1996; 13:483.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Crystal methamphetamine use, Internet and other factors likely fueling increases in STDs, risk behavior among gay and bisexual men. Available at: file://www.cdc.gov/stdconference/2004/MediaRelease/CrystalMeth.htm (Accessed on February 06, 2006).",
"    </li>",
"    <li>",
"     National Institute on Drug Abuse. Club Drugs. Available at: www.nida.nih.gov/drugpages/clubdrugs.html (Accessed on July 27, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/38\">",
"      Pillard, RC. Sexual orientation and mental disorder. Psychiatr Ann 1988; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/39\">",
"      Gershman H. The stress of coming out. Am J Psychoanal 1983; 43:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/40\">",
"      Herrell R, Goldberg J, True WR, et al. Sexual orientation and suicidality: a co-twin control study in adult men. Arch Gen Psychiatry 1999; 56:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/41\">",
"      Fichter MM, Daser C. Symptomatology, psychosexual development and gender identity in 42 anorexic males. Psychol Med 1987; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/42\">",
"      McClennen JC. Domestic violence between same-gender partners: recent findings and future research. J Interpers Violence 2005; 20:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/43\">",
"      Ard KL, Makadon HJ. Addressing intimate partner violence in lesbian, gay, bisexual, and transgender patients. J Gen Intern Med 2011; 26:930.",
"     </a>",
"    </li>",
"    <li>",
"     Island D, Letellier P. Men Who Beat the Men Who Love Them: Battered Gay Men and Domestic Violence, Haworth Press, Binghamton, NY 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20120/abstract/45\">",
"      Willis DG. Hate crimes against gay males: an overview. Issues Ment Health Nurs 2004; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     Gay and Lesbian Medical Association. Guidelines: Creating a safe clinical environment for lesbian, gay, bisexual, transgender, and intersex (LGBTI) patients. San Francisco, CA, Gay and Lesbian Medical Association.",
"    </li>",
"    <li>",
"     National Lesbian &amp; Gay Health Association and the Mautner Project for Lesbians with Cancer (1997). Check list for optimal care of lesbian, gay, bisexual, and transgender clients. Removing Barriers to Health Care for Lesbian, Gay, Bisexual, and Transgender Clients: A Model Provider Education Program, Trainer's Handbook.",
"    </li>",
"    <li>",
"     Zhani EE. Joint Commission focuses on improving care for LGBT patients: New guide provides strategies, examples, resources for hospitals. The Joint Commission 2011. Available at: file://www.jointcommission.org/improving_care_for_lgbt_patients/ (Accessed on November 15, 2011).",
"    </li>",
"    <li>",
"     Institute of Medicine. The Health of Lesbian, Gay, Bisexual, and Transgender People:, The National Academies Press, Washington, DC 2011.",
"    </li>",
"    <li>",
"     Affordable Care Act to improve data collection, reduce health disparities. US Department of Health and Human Services 2011. Available at: file://www.hhs.gov/news/press/2011pres/06/20110629a.html (Accessed on September 28, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7577 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20120=[""].join("\n");
var outline_f19_41_20120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY AND IDENTITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OBTAINING A HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ISSUES TO TARGET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H221828025\">",
"      Sexually transmitted diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H221828315\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Substance and tobacco abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Tobacco abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Alcohol use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Drug abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Behavioral health and mental disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Domestic violence, sexual assault, and hate crimes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MAKING CARE ACCESSIBLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/44/41670?source=related_link\">",
"      Approach to immunizations in healthy adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12761?source=related_link\">",
"      Classification and epidemiology of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8408?source=related_link\">",
"      Screening for Chlamydia trachomatis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2630?source=related_link\">",
"      Transsexualism: Epidemiology, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20121="Everolimus: Pediatric drug information";
var content_f19_41_20121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Everolimus: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"    see \"Everolimus: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38070?source=see_link\">",
"    see \"Everolimus: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10223925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7418605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor&reg;;",
"     </li>",
"     <li>",
"      Afinitor&reg; Disperz;",
"     </li>",
"     <li>",
"      Zortress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13209898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Afinitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13307736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, mTOR Kinase Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13307778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"      see \"Everolimus: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;1 year and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable. Afinitor&reg; Disperz is only indicated for the treatment of subependymal giant cell astrocytoma (SEGA), in conjunction with therapeutic monitoring. Do not combine formulations to achieve desired dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Subependymal giant cell astrocytoma (SEGA):",
"     </b>",
"     Afinitor&reg;; Afinitor&reg; Disperz: Oral: Initial: 4.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily; round to nearest tablet (tablet or tablet for oral suspension) size; assess trough concentrations 2 weeks after initiation or dosage modification; adjust maintenance dose if needed at 2-week intervals to achieve and maintain serum trough concentrations between 5 and 15 ng/mL; monitor trough concentrations routinely; once stable dose is attained and BSA is stable throughout treatment, monitor trough concentrations every 6-12 months; monitor every 3-6 months if BSA is changing. Continue until disease progression or unacceptable toxicity. Serum trough concentrations should also be assessed if dosage form switched (tablets or tablets for oral suspension), hepatic function changes or therapy with a CYP3A4 or P-gp inducer or inhibitor is modified (initiated, dose change, or discontinued).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If trough &lt;5 ng/mL: Increase dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If trough &gt;15 ng/mL: Reduce dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If dose reduction necessary in patients receiving the lowest strength available, administer every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Transplantation; renal, rejection prophylaxis:",
"     </b>",
"     Zortress&reg;: Limited data available: Initial: 0.8 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily (maximum single dose: 1.5 mg) to maintain serum concentration: 3-6 ng/mL; reported start time of therapy variable: Within 48 hours post-transplantation was used in a multicenter, international trial of 19 pediatric patients; another trial began at 2 weeks after transplantation (single center, n=20 pediatric patients); a trial evaluating use for 3 years in pediatric patients (&lt;16 years), the mean reported dose was 1.53 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day and no untoward adverse effects were noted (Ettenger, 2008; Hoyer, 2003; Pape, 2007; Pape, 2010; Pape, 2011; Van-Damme-Lombaerts, 2002; Vester, 2002). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable; Afinitor&reg; Disperz is only indicated for the treatment of subependymal giant cell astrocytoma (SEGA), in conjunction with therapeutic monitoring. Do not combine formulations to achieve desired dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Breast cancer, advanced, hormone receptor-positive, HER2-negative:",
"     </b>",
"     Afinitor&reg;: Oral: 10 mg once daily (in combination with exemestane); continue treatment until no longer clinically beneficial or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pancreatic neuroendocrine tumors, advanced (PNET):",
"     </b>",
"     Afinitor&reg;: 10 mg once daily; continue treatment until no longer clinically benefiting or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Renal cell cancer (RCC), advanced:",
"     </b>",
"     Afinitor&reg;: 10 mg once daily; continue treatment until no longer clinically benefiting or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Renal angiomyolipoma:",
"     </b>",
"     Afinitor&reg;: Oral: 10 mg once daily; continue treatment until no longer clinically beneficial or until unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Subependymal giant cell astrocytoma (SEGA):",
"     </b>",
"     Afinitor&reg;: Body surface area-based dosing: Oral: Initial dose: 4.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily; round to nearest tablet (tablet or tablet for oral suspension) size. Assess trough concentrations 2 weeks after initiation or dosage modification; adjust maintenance dose if needed at 2-week intervals to achieve and maintain serum trough concentrations between 5 and 15 ng/mL; monitor trough concentrations routinely; once stable dose is attained and BSA is stable throughout treatment, monitor trough concentrations every 6-12 months; monitor every 3-6 months if BSA is changing. Continue until disease progression or unacceptable toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If trough &lt;5 ng/mL: Increase dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If trough &gt;15 ng/mL: Reduce dose by 2.5 mg/day (tablets) or 2 mg/day (tablets for oral suspension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     If dose reduction necessary in patients receiving the lowest strength available, administer every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Transplantation; renal, rejection prophylaxis:",
"     </b>",
"     Zortress&reg;: Initial: 0.75 mg twice daily; adjust maintenance dose if needed at a 4- to 5-day interval (from prior dose adjustment) based on serum concentrations, tolerability, and response; goal serum concentration is between 3 and 8 ng/mL (based on an LCMSMS assay method).",
"     <b>",
"      Note:",
"     </b>",
"     For use in renal transplantation, administer in combination with basiliximab induction and concurrently with cyclosporine (dose adjustment required) and corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers and/or P-gp inhibitors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CYP3A4 inducers: Strong inducers: Avoid concomitant administration with strong CYP3A4 inducers; if concomitant use cannot be avoided, consider adjusting everolimus dose upward in 5 mg increments up to 20 mg daily, with careful monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce the everolimus to the dose used prior to initiation of the CYP3A4 inducer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CYP3A4 or P-gp inhibitors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Strong inhibitors: Avoid concomitant administration with strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Moderate inhibitors: Reduce dose to 2.5 mg once daily; may consider increasing from 2.5 mg to 5 mg once daily based on patient tolerance. When the moderate inhibitor is discontinued, allow ~2-3 days to elapse prior to adjusting the everolimus upward to the dose used prior to initiation of the moderate inhibitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      SEGA:",
"     </b>",
"     Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CYP3A4 inducers: Strong inducers: Avoid concomitant administration with strong CYP3A4 inducers; if concomitant cannot be avoided, an initial starting everolimus dose of 9 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily is recommended, or double the everolimus dose; individualize subsequent doses based on therapeutic drug monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce the everolimus to the dose used prior to initiation of the CYP3A4 inducer; reassess trough concentration after 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     CYP3A4 or P-gp inhibitors:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Strong inhibitors: Avoid concomitant administration with strong CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">",
"     Moderate inhibitors: Initial everolimus dose: 2.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily or reduce dose by 50% (if dose reduction is required for patients receiving the lowest strength available, consider alternate day dosing); assess trough concentrations after 2 weeks; individualize dosing based on therapeutic drug monitoring. When the moderate inhibitor is discontinued, adjust the everolimus upward to the dose used prior to initiation of the moderate inhibitor; reassess trough concentrations after 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Transplantation; renal:",
"     </b>",
"     Children, Adolescents, and Adults: Dosage adjustments may be necessary based on everolimus serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild hepatic impairment (Child-Pugh class A):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </b>",
"     Adults: Reduce dose to 7.5 mg once daily; if not tolerated, may further reduce to 5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      SEGA:",
"     </b>",
"     Children, Adolescents, and Adults: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor 2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5-15 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Transplantation, renal:",
"     </b>",
"     No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate hepatic impairment (Child-Pugh class B):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </b>",
"     Adults: Reduce dose to 5 mg once daily if not tolerated, may further reduce to 2.5 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      SEGA:",
"     </b>",
"     Children, Adolescents, and Adults: Adjustment to initial dose may not be necessary; subsequent dosing is based on therapeutic drug monitoring (monitor 2 weeks after initiation, dosage modifications, or after any change in hepatic status; target trough concentration: 5-15 ng/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <b>",
"      Transplantation, renal:",
"     </b>",
"     Adults: Reduce initial dose by 50%; individualize subsequent dosing based on therapeutic drug monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Severe hepatic impairment (Child-Pugh class C):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Breast cancer, PNET, RCC, renal angiomyolipoma:",
"     </b>",
"     Adults: If potential benefit outweighs risks, a maximum dose of 2.5 mg once daily may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      SEGA:",
"     </b>",
"     Children, Adolescents, and Adults: Reduce initial dose to 2.5 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once daily (or current dose by ~50%); subsequent dosing is based on therapeutic drug monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Transplantation, renal:",
"     </b>",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (pharmacokinetics have not been studied in severe hepatic impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"     Children, Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      Breast cancer (adjustments apply to everolimus), PNET, RCC, renal angiomyolipoma, SEGA:",
"     </b>",
"     Reduce everolimus dose by ~50% if dosage adjustment is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <i>",
"      Noninfectious pneumonitis:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 1 (asymptomatic radiological changes suggestive of pneumonitis): No dosage adjustment necessary; monitor appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 2 [symptomatic but not interfering with activities of daily living (ADL)]: Consider interrupting treatment, rule out infection, and consider corticosteroids until symptoms improve to &le;grade 1; reinitiate at a lower dose. Discontinue if recovery does not occur within 4 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 3 (symptomatic, interferes with ADL; oxygen indicated): Interrupt treatment until symptoms improve to &le;grade 1; rule out infection and consider corticosteroid treatment; may reinitiate at a lower dose. If grade 3 toxicity recurs, consider discontinuing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 4 (life-threatening; ventilatory support indicated): Discontinue treatment; rule out infection; consider corticosteroid treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Stomatitis (avoid the use of products containing alcohol, hydrogen peroxide, iodine, or thyme derivatives):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 1 (minimal symptoms, normal diet): No dosage adjustment necessary; manage with mouth wash (nonalcoholic or salt water) several times a day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 2 (symptomatic but can eat and swallow modified diet): Interrupt treatment until symptoms improve to &le;grade 1; reinitiate at same dose; if stomatitis recurs at grade 2, interrupt treatment until symptoms improve to &le;grade 1 and then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoate, tetracaine, menthol, or phenol) &plusmn; topical (oral) corticosteroids (eg, triamcinolone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 3 (symptomatic and unable to orally aliment or hydrate adequately): Interrupt treatment until symptoms improve to &le;grade 1; then reinitiate at a lower dose. Also manage with topical (oral) analgesics (eg, benzocaine, butyl aminobenzoate, tetracaine, menthol, or phenol) &plusmn; topical (oral) corticosteroids (eg, triamcinolone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 4 (life-threatening symptoms): Discontinue treatment; initiate appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Metabolic toxicity (eg, hyperglycemia, dyslipidemia):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 1: No dosage adjustment necessary; initiate appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 2: No dosage adjustment necessary; manage with appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 3: Temporarily interrupt treatment; reinitiate at a lower dose; manage with appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 4: Discontinue treatment; manage with appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Nonhematologic toxicities (excluding pneumonitis, stomatitis, and metabolic toxicity):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 1: If toxicity is tolerable, no dosage adjustment necessary; initiate appropriate medical intervention and monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 2: If toxicity is tolerable, no dosage adjustment necessary; initiate appropriate medical intervention and monitor. If toxicity becomes intolerable, temporarily interrupt treatment until improvement to &le;grade 1 and reinitiate at the same dose; if toxicity recurs at grade 2, temporarily interrupt treatment until improvement to &le;grade 1 and then reinitiate at a lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 3: Temporarily interrupt treatment until improvement to &le;grade 1; initiate appropriate medical intervention and monitor. May reinitiate at a lower dose; if toxicity recurs at grade 3, consider discontinuing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Grade 4 (life-threatening symptoms): Discontinue treatment; initiate appropriate medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      SEGA:",
"     </b>",
"     <i>",
"      Other severe/intolerable adverse reactions:",
"     </i>",
"     Temporarily reduce dose (by ~50% from prior dose) and/or temporarily interrupt treatment; if dose reduction is required for patients receiving the lowest available strength, consider alternate day dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Transplantation, renal:",
"     </b>",
"     <i>",
"      Evidence of polyoma virus infection or PML:",
"     </i>",
"     Consider reduced immunosuppression (taking into account the allograft risks associated with decreased immunosuppression).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7674251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afinitor&reg;: 2.5 mg, 5 mg, 7.5 mg, 10 mg [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zortress&reg;: 0.25 mg, 0.5 mg, 0.75 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7674088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14949342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Afinitor Disperz (tablets for oral suspension): FDA approved August 2012; anticipated availability in November 2012. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10223926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zortress&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM209840.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM209840.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13307877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be taken with or without food; to reduce variability, take consistently with regard to food; if using for SEGA, breast cancer, PNET, renal angiolipoma, or RCC, administer at the same time each day; if using for renal transplantation, administer consistently ~12 hours apart and at the same time as cyclosporine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Swallow tablet whole with a glass of water; do not chew or crush; do not use tablets that are crushed or broken; avoid contact with or exposure to crushed or broken tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets for oral suspension: Administer as a suspension only. Administer immediately after preparation; discard if not administered within 60 minutes after preparation. Prepare suspension in water only. Do not break or crush tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Preparation in an oral syringe:",
"     </i>",
"     Place dose into 10 mL oral syringe (maximum 10 mg/syringe; use an additional syringe for doses &gt;10 mg). Draw ~5 mL of water and ~4 mL of air into oral syringe; allow to sit (tip up) in a container until tablets are in suspension (3 minutes). Gently invert syringe 5 times immediately prior to administration; administer contents (dose), and then add ~5 mL water and ~4 mL of air to same syringe, swirl to suspend remaining particles, and administer entire contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Preparation in a small glass:",
"     </i>",
"     Place dose into a small glass (&le;100 mL) containing ~25 mL water (maximum 10 mg/glass; use an additional glass for doses &gt;10 mg); allow to sit until tablets are in suspension (3 minutes). Stir gently with spoon immediately prior to administration; administer contents, then add ~25 mL water to same glass, swirl with same spoon to suspend remaining particles and administer entire contents.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13307769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets and tablets for suspension: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13307737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Afinitor&reg;: Treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis which requires intervention, but cannot be curatively resected (FDA approved in ages &ge;1 year and adults); treatment of advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (in combination with exemestane and after letrozole or anastrozole failure (FDA approved in adults); treatment of advanced renal cell cancer (RCC), after sunitinib or sorafenib failure (FDA approved in adults); treatment of renal angiomyolipoma with tuberous sclerosis complex (TSC) not requiring immediate surgery (FDA approved in adults); treatment of advanced, metastatic, or unresectable pancreatic neuroendocrine tumors (PNET) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Afinitor&reg; Disperz: Treatment of SEGA associated with TSC which requires intervention, but cannot be curatively resected (FDA approved in ages &ge;1 year and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zortress&reg;: Prophylaxis of organ rejection in patients at low-moderate immunologic risk receiving renal transplants (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7674085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Everolimus may be confused with sirolimus, tacrolimus, temsirolimus",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable; do not combine formulations to achieve desired dose.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7674167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Angina, atrial fibrillation, chest discomfort, chest pain, deep vein thrombosis, edema (generalized), heart failure, hyper-/hypotension, hypertensive crisis, palpitation, peripheral edema, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Agitation, anxiety/aggression/behavioral disturbance, chills, depression, dizziness, fatigue, fever, hallucination, hemiparesis, hypesthesia, insomnia, malaise, migraine, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Acne, acneiform dermatitis, alopecia, cellulitis, contact dermatitis, dry skin, eczema, erythema, excoriation, hirsutism, incision complications, hyperhydrosis, hypertrichosis, nail disorders, onychoclasis, palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), papule, pityriasis rosea, pruritus, rash, skin lesions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Acidosis, amenorrhea, cushingoid syndrome, dehydration, diabetes mellitus, dyslipidemia, dysmenorrhea, gout, hypercholesterolemia, hyper-/hypocalcemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hypophosphatemia, hyperlipidemia, hyperparathyroidism, hypertriglyceridemia, hyperuricemia, hypomagnesemia, hyponatremia, iron deficiency, menorrhagia, menstrual irregularities, metrorrhagia, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal distention, abdominal pain, ageusia, anorexia, appetite decreased, constipation, diarrhea, dyspepsia, dysphagia, epigastric discomfort, flatulence, gastritis, gastroenteritis, gastroesophageal reflux, gingival hypertrophy, hematemesis, hemorrhoids, ileus, nausea, peritonitis, stomatitis, taste alteration, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Bladder spasm, dysuria, erectile dysfunction, ovarian cysts, pollakiuria, polyuria, pyuria, scrotal edema, urinary retention, urinary tract infection, urinary urgency, vaginal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia, hemorrhage, leukocytosis, leukopenia, lymphadenopathy, lymphocytopenia, neutropenia, PTT increased, thrombocythemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, ALT increased, bilirubin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, jaw pain, joint swelling, limb pain, muscle spasm, musculoskeletal pain, myalgia, osteonecrosis, osteopenia, osteoporosis, paresthesia, spondylitis, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision, cataract, conjunctivitis, eyelid edema, ocular hyperemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Otitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: BUN increased, creatinine increased, hematuria, hydronephrosis, interstitial nephritis, proteinuria, renal artery thrombosis, renal failure, renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Atelectasis, bronchitis, cough, dyspnea, epistaxis, nasal congestion, nasopharyngitis, pharyngitis, pharyngolaryngeal pain, pleural effusion, pneumonia, pneumonitis (includes alveolitis, interstitial lung disease, lung infiltrate, pulmonary alveolar hemorrhage, pulmonary toxicity), pulmonary edema, rhinitis, rhinorrhea, sinus congestion, sinusitis, upper respiratory infection, wheezing,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: BK virus infection, candidiasis, hypersensitivity (includes anaphylaxis, dyspnea, flushing, chest pain, angioedema), infection, night sweats",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Aspergillosis, azoospermia, cardiac arrest, fluid accumulation, graft thrombosis, hepatic cholestasis, hepatitis B reactivation, lymphoma, oligospermia, pancreatitis, pancytopenia, polyoma virus infection (BK virus), progressive multiple leukoencephalopathy (PML), pulmonary embolism, respiratory distress, sepsis, skin cancer, synovitis (severe), testosterone levels decreased, thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS), wound healing impaired",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13307738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to everolimus or any component; hypersensitivity to sirolimus or other rapamycin derivatives",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13307760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; everolimus exposure is increased in patients with moderate hepatic impairment; consider dosage reductions; use is not recommended in patients with severe impairment (has not been studied). For patients with breast cancer, PNET, RCC, or renal angiomyolipoma with mild and moderate hepatic impairment, reduced doses are recommended; in patients with severe hepatic impairment, use is recommended (at reduced doses) if the potential benefit outweighs risks. For patients with SEGA, reduced doses may be needed (based on therapeutic drug monitoring) for mild and moderate hepatic impairment, and are recommended in severe hepatic impairment; monitor trough levels. Reduced doses are also recommended in renal transplant patients with moderate hepatic impairment; pharmacokinetic information does not exist for renal transplant patients with severe impairment, although an AUC increase greater than observed in moderate impairment is likely.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with hyperlipidemia; may increase serum lipids (cholesterol and triglycerides); higher everolimus serum concentrations are associated with an increased risk for hyperlipidemia; use has not been studied in patients with baseline cholesterol &gt;350 mg/dL; antihyperlipidemic therapy may not normalize levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Increases in serum glucose are common; may alter insulin and/or oral hypoglycemic therapy requirements in patients with diabetes; the risk for new onset diabetes is increased with everolimus use after transplantation. Patients should not be immunized with live virus vaccines during or shortly after treatment and should avoid close contact with individuals recently vaccinated with live virus vaccines; consider the timing of routine immunizations prior to the start of therapy in pediatric patients treated for SEGA.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Azoospermia and oligospermia have been observed in males. Avoid use in patients with hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; may result in diarrhea and malabsorption. In renal transplantation, everolimus should only be used by physicians experienced in immunosuppressive therapy and management of transplant patients",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; adequate laboratory and supportive medical resources must be readily available.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13307739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Everolimus has immunosuppressant properties which may result in infection",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; the risk of developing bacterial (including mycobacterial), viral, fungal, and protozoal infections and for local, opportunistic (including polyomavirus infection), systemic infections, and/or sepsis is increased. Polyomavirus infection in transplant patients may be serious and/or fatal. Polyoma virus-associated nephropathy (due to BK virus), which may result in serious cases of deteriorating renal function and renal graft loss, has been observed with use in renal transplantation. JC virus-associated progressive multiple leukoencephalopathy (PML) may also be associated with everolimus use in transplantation. Reduced immunosuppression should be considered with evidence of polyoma virus infection or PML. Reactivation of hepatitis B has been observed in patients with RCC. Resolve pre-existing invasive fungal infections prior to treatment initiation. Monitor for signs and symptoms of infection during treatment. Discontinue if invasive systemic fungal infection is diagnosed (and manage with appropriate antifungal therapy). Everolimus use may delay wound healing and increase the occurrence of wound-related complications (eg, wound dehiscence, infection, incisional hernia, lymphocele, seroma); may require surgical intervention. Decreases in hemoglobin, neutrophils, platelets, and lymphocytes have been reported with use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Noninfectious pneumonitis (sometimes fatal) has been observed with mTOR inhibitors, including everolimus; symptoms include dyspnea, cough, hypoxia, and/or pleural effusion; promptly evaluate worsening respiratory symptoms. Moderate symptoms may require treatment interruption followed by dose reduction or corticosteroid therapy; severe symptoms may require discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immunosuppressant use may result in the development of malignancy, including lymphoma and skin cancer",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; the risk is associated with treatment intensity and the duration of therapy. To minimize the risk for skin cancer, exposure to sunlight and ultraviolet light should be limited, protective clothing worn, and sunscreen used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to the increased risk for nephrotoxicity in renal transplantation, avoid standard doses of cyclosporine in combination with everolimus; reduced cyclosporine doses are recommended when everolimus is used in combination with cyclosporine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Therapeutic monitoring of cyclosporine and everolimus concentrations is recommended. Monitor for proteinuria; the risk of proteinuria is increased when everolimus is used in combination with cyclosporine and with higher serum everolimus concentrations. Everolimus and cyclosporine combination therapy may increase the risk for thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS) syndrome; monitor blood counts. An increased risk of renal arterial and venous thrombosis has been reported with use in renal transplantation, generally within the first 30 days after transplant; may result in graft loss",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Elevations in serum creatinine and acute renal failure (some cases fatal) have been also observed with everolimus use for renal cell cancer; monitor renal function. An increased incidence of rash, infection, and dose interruptions have been reported in patients with renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute) who received mTOR inhibitors for the treatment of renal cell cancer (Gupta, 2011); pharmacokinetic studies have not been conducted; dosage adjustments are not required based on renal impairment. The safety and efficacy of everolimus in patients with high-immunologic risk in renal transplantation or in solid organ transplant other than renal have not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid concomitant use with strong CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital) and strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, atazanavir, saquinavir, ritonavir, indinavir, delavirdine, fosamprenavir, nelfinavir, nefazodone, grapefruit juice). Everolimus dosage modification and therapeutic drug monitoring may be needed if concomitant use with strong CYP3A4 inducers cannot be avoided. Use with caution with concomitant moderate CYP3A4 inhibitors and/or P-gp inhibitors; decreased everolimus doses are recommended. In renal transplant patients, avoid the use of certain HMG-CoA reductase inhibitors (eg, simvastatin and lovastatin); may increase the risk for rhabdomyolysis due to the potential interaction with cyclosporine (which is given in combination with everolimus for renal transplantation ).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is associated with mouth ulcers, mucositis, and stomatitis; avoid the use of alcohol-, peroxide, iodine, or thyme-based mouthwashes. Due to the high potential for drug interactions, avoid the use of systemic antifungals unless fungal infection has been diagnosed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Everolimus is associated with the development of angioedema; concomitant use with other agents known to cause angioedema (eg, ACE inhibitors) may increase the risk. Generalized edema, including peripheral edema and lymphedema, and local fluid accumulation (eg, pericardial effusion, pleural effusion, ascites) may also occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Increased mortality (usually associated with infections) within the first 3 months after transplant was noted in a study of patients with",
"     <i>",
"      de novo",
"     </i>",
"     heart transplant receiving immunosuppressive regimens containing everolimus (with or without induction therapy); use in heart transplantation is not recommended",
"     <b>",
"      [U.S. Boxed Warning ]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tablets (Afinitor&reg;, Zortress&reg;) and tablets for oral suspension (Afinitor&reg; Disperz) are not interchangeable; do not combine formulations to achieve desired dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7710406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Everolimus may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Everolimus. Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Everolimus. Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Everolimus. Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Everolimus. Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Everolimus. Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Everolimus. Management: Concurrent use of Afinitor brand everolimus with St Johns wort (SJW) is not recommended. Zortress brand everolimus prescribing information cautions that SJW may decrease everolimus concentrations, though no specific dose adjustment is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13307768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grapefruit juice may increase levels of everolimus; avoid use. A high-fat meal decreases the maximum serum concentration by 54%; decreases in systemic exposure (AUC)  with a light-fat meal and a high-fat meal were 32% and 22%, respectively.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7674093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (Afinitor&reg;) / C (Zortress&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7674094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryotoxicity, fetotoxicity, malformations, and growth retardation were observed in animal reproduction studies with exposures lower than expected with human doses. Based on the mechanism of action, may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised to avoid pregnancy. Women of childbearing potential should use highly effective birth control during treatment, and continue for 8 weeks after everolimus discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13307878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and periodic), liver function, serum creatinine, urinary protein, and BUN (baseline and periodic); fasting serum glucose and lipid profile (baseline and periodic); monitor for signs and symptoms of infection, noninfectious pneumonitis, or malignancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     SEGA: Monitor everolimus serum trough concentrations approximately 2 weeks after treatment initiation, 2 weeks after dose modifications, and after initiation or dose modification of concomitant CYP3A4 and/or P-gp inducers or inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transplantation; renal: Monitor serum trough concentrations (based on an LCMSMS assay method), especially in patients with hepatic impairment, with concomitant CYP3A4 inhibitors and inducers, and when cyclosporine formulations or doses are changed; dosage adjustments should be made on trough concentrations obtained 4-5 days after previous dosage adjustment; monitor cyclosporine concentrations and proteinuria.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13307879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommended range for everolimus serum concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SEGA: 5-15 ng/mL (high concentrations may be associated with larger reductions in SEGA volumes; responses have been observed at concentrations as low as 5 ng/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transplantation; renal: 3-8 ng/mL (based on LCMSMS assay method); in pediatric studies, reported target range: 3-6 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13307770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Everolimus is a macrolide immunosuppressant and an m-TOR inhibitor which has antiproliferative and antiangiogenic properties and reduces protein synthesis and cell proliferation by binding to the FK binding protein-12 (FKBP-12), an intracellular protein, to form a complex that inhibits activation of mTOR (mammalian target of rapamycin) serine-threonine kinase activity. Everolimus also reduces angiogenesis by inhibiting vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF-1) expression. Angiomyolipomas may occur due to unregulated m-TOR activity in TSC-associated renal angiomyolipoma (Budde, 2012); everolimus reduces lipoma volume (Bissler, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13307771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid but moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     apparent: 128-589 L; volume of distribution in pediatric patients (3-16 years) lower than adults (Van-Damme-Lombaerts, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~74%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensively metabolized via CYP3A4; forms 6 weak metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~30 hours; in pediatric patients (3-16 years), half-life similar to adult data (Van-Damme-Lombaerts, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Feces (80%, based on solid organ transplant studies); urine (~5%, based on solid organ transplant studies); clearance in pediatric patients lower than adults possibly due to distributive differences (Van-Damme-Lombaerts, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13307889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38070?source=see_link\">",
"      see \"Everolimus: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush or chew tablets; take whole at same time each day with a full glass of water; avoid contact with crushed or broken tables. Avoid grapefruit and grapefruit juice while taking this medication. Do not start any new medications (prescription or OTC) or herbal products without discussing with physician; some medications can affect everolimus serum concentrations. Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake. Regularly scheduled laboratory tests are required while on this medication. Avoid exposure to persons who are ill or recently received a live vaccine (eg, influenza intranasal); susceptibility to infection is high. If diabetic, monitor glucose levels closely and notify prescriber of significant changes; this medication can affect glucose control and diabetic medications may need to be adjusted. May cause headache, fatigue, loss of appetite, nausea, vomiting, or mouth sores. Report immediately changes in respiratory status (difficulty breathing, dyspnea, unusual cough, fever); swelling of extremities or unusual weight gain; persistent diarrhea, gastrointestinal upset, abdominal pain, or blood in stool; signs or symptoms of any urinary tract infection (difficulty urinating, burning on urination, perineal itching); infection (fever, chills); or delayed wound healing. Limit exposure to sunlight and UV light. Females of childbearing age should avoid pregnancy during treatment with everolimus and 8 weeks after therapy is stopped.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F12825622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Tablets:",
"     </b>",
"     An oral liquid may be prepared using tablets. Disperse tablet in ~30 mL (1 oz) of water; gently stir. Administer and rinse container with additional 30 mL (1 oz) water and administer to ensure entire dose is administered. Administer immediately after preparation.",
"    </p>",
"    <div class=\"reference\">",
"     Afinitor&reg; prescribing information, East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2012.",
"    </div>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Tablets for oral suspension:",
"     </b>",
"     Administer as a suspension only. Administer immediately after preparation; discard if not administered within 60 minutes after preparation. Prepare suspension in water only. Do not break or crush tablets.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Preparation in an oral syringe:",
"     </i>",
"     Place dose into 10 mL oral syringe (maximum 10 mg/syringe; use an additional syringe for doses &gt;10 mg). Draw ~5 mL of water and ~4 mL of air into oral syringe; allow to sit (tip up) in a container until tablets are in suspension (3 minutes). Gently invert syringe 5 times immediately prior to administration; administer contents, then add ~5 mL water and ~4 mL of air to same syringe, swirl to suspend remaining particles and administer entire contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Preparation in a small glass:",
"     </i>",
"     Place dose into a small glass (&le;100 mL) containing ~25 mL water (maximum 10 mg/glass; use an additional glass for doses &gt;10 mg); allow to sit until tablets are in suspension (3 minutes). Stir gently with spoon immediately prior to administration; administer contents, then add ~25 mL water to same glass, swirl with same spoon to suspend remaining particles and administer entire contents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Administer immediately after preparation; discard if not administered within 60 minutes after preparation.",
"    </p>",
"    <div class=\"reference\">",
"     Afinitor&reg; and Afinitor&reg; Disperz prescribing information, East Hanover, NJ: Novartis Pharmaceuticals Corporation, August 2012",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bissler JJ, Kingswood JC, Zonnenberg BA, et al, &ldquo;Everolimus Therapy for Angiomyolipoma in Patients With Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis: Results From EXIST-2,&rdquo;",
"      <i>",
"       J Clin Oncology",
"      </i>",
"      , 2012, 30(Supp 5):356.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Budde K and Gaedeke J, &ldquo;Tuberous Sclerosis Complex-Associated Angiomyolipomas: Focus on mTOR Inhibition,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2012, 59(2):276-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/22130643/pubmed\" id=\"22130643\" target=\"_blank\">",
"        22130643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ettenger R, Hoyer PF, Grimm P, et al, \"Multicenter Trial of Everolimus in Pediatric Renal Transplant Recipients: Results at Three Year,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2008, (4):456-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/18466433/pubmed\" id=\"18466433\" target=\"_blank\">",
"        18466433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoyer PF, Ettenger R, Kovarik JM, et al, \"Everolimus in Pediatric",
"      <i>",
"       de nova",
"      </i>",
"      Renal Transplant Patients,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2003, 75(12):2082-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/12829916/pubmed\" id=\"12829916\" target=\"_blank\">",
"        12829916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirchner GI, Meier-Wiedenbach I, and Manns MP, \"Clinical Pharmacokinetics of Everolimus,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2004, 43(2):83-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/14748618/pubmed\" id=\"14748618\" target=\"_blank\">",
"        14748618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovarik JM, Sabia HD, Figueiredo J, et al, \"Influence of Hepatic Impairment on Everolimus Pharmacokinetics: Implications for Dose Adjustment,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2001, 70(5):425-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/11719728/pubmed\" id=\"11719728\" target=\"_blank\">",
"        11719728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krueger DA, Care MM, Holland K, et al, \"Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(19):1801-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/21047224/pubmed\" id=\"21047224\" target=\"_blank\">",
"        21047224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorber MI, Ponticelli C, Whelchel J, et al, &ldquo;Therapeutic Drug Monitoring for Everolimus in Kidney Transplantation Using 12-Month Exposure, Efficacy, and Safety Data,&rdquo;",
"      <i>",
"       Clin Transplant",
"      </i>",
"      , 2005, 19(2):145-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/15740547/pubmed\" id=\"15740547\" target=\"_blank\">",
"        15740547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Donnell A, Faivre S, Burris HA 3rd, et al, \"Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(10):1588-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/18332470/pubmed\" id=\"18332470\" target=\"_blank\">",
"        18332470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pape L, Ahlenstiel T, Ehrich JH, et al, \"Reversal of Loss of Glomerular Filtration Rate in Children With Transplant Nephropathy After Switch to Everolimus and Low-Dose Cyclosporine A,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2007, 11(3):291-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/17430485/pubmed\" id=\"17430485\" target=\"_blank\">",
"        17430485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pape L, Lehner F, Blume C, et al, \"Pediatric Kidney Transplantation Followed by",
"      <i>",
"       de novo",
"      </i>",
"      Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year Data,\"",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2011, 92(6):658-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/21804444/pubmed\" id=\"21804444\" target=\"_blank\">",
"        21804444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pape L, Offner G, Kreuzer M, et al, \"",
"      <i>",
"       De novo",
"      </i>",
"      Therapy With Everolimus, Low-Dose Ciclosporine A, Basiliximab and Steroid Elimination in Pediatric Kidney Transplantation,\"",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2010, 10(10):2349-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/20840473/pubmed\" id=\"20840473\" target=\"_blank\">",
"        20840473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tabernero J, Rojo F, Calvo E, et al, \"Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors,\" J Clin Oncol. 2008 Apr 1;26(10):1603-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Damme-Lombaerts R, Webb NA, Hoyer PF, et al, \"Single-Dose Pharmacokinetics and Tolerability of Everolimus in Stable Pediatric Renal Transplant Patients,\"",
"      <i>",
"       Pediatr Transplant",
"      </i>",
"      , 2002, 6(2):147-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/12000472/pubmed\" id=\"12000472\" target=\"_blank\">",
"        12000472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vester U, Kranz B, Wehr S, et al, \"Everolimus (Certican) in Combination With Neoral in Pediatric Renal Transplant Recipients: Interim Analysis After 3 Months,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2002, 34(6):2209-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/41/20121/abstract-text/12270366/pubmed\" id=\"12270366\" target=\"_blank\">",
"        12270366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17063 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20121=[""].join("\n");
var outline_f19_41_20121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10223925\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7418605\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13209898\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307736\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307778\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674251\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674088\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14949342\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10223926\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307877\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307769\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307737\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674167\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307738\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307760\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307739\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837969\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710406\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307768\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674093\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7674094\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307878\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307879\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307770\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307771\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307889\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12825622\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17063\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17063|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=related_link\">",
"      Everolimus: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/11/38070?source=related_link\">",
"      Everolimus: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20122="Chronic menorrhagia or anovulatory uterine bleeding";
var content_f19_41_20122=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic menorrhagia or anovulatory uterine bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20122/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20122/contributors\">",
"     Howard A Zacur, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20122/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20122/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/41/20122/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/41/20122/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/41/20122/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic heavy or prolonged uterine bleeding is a common gynecologic problem. Such bleeding may be ovulatory or anovulatory. Chronic heavy or prolonged uterine bleeding can result in anemia, interfere with daily activities, and raise concerns about uterine cancer. Most women with heavy or prolonged uterine bleeding require medical attention, but can be managed on a nonacute, outpatient basis. Occasionally, uterine bleeding is severe enough to necessitate immediate medical evaluation and treatment.",
"   </p>",
"   <p>",
"    Chronic heavy or prolonged uterine bleeding in nonpregnant premenopausal women will be reviewed here. Uterine bleeding that requires urgent treatment, the general evaluation of abnormal uterine bleeding, menorrhagia in patients with von Willebrand disease, and uterine bleeding in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=see_link\">",
"     \"Managing an episode of severe or prolonged uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of von Willebrand disease\", section on 'Treatment of excessive menstrual bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average menstrual cycle lasts up to seven days and the amount of menstrual blood loss is 35 to 40 mL per cycle, but the range is wide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Menorrhagia is defined as menstrual blood loss greater than 80 mL. However, the term menorrhagia is applied variably to ovulatory or anovulatory uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/3\">",
"     3",
"    </a>",
"    ]. In this review, we will refer to heavy menstrual bleeding (&gt;80 mL), and specify ovulatory or anovulatory as necessary.",
"   </p>",
"   <p>",
"    Prolonged menses are defined as longer than seven days; in this review, we will apply this definition to either ovulatory or anovulatory bleeding and address women with chronic prolonged uterine bleeding.",
"   </p>",
"   <p>",
"    Management of an isolated episode of prolonged bleeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=see_link\">",
"     \"Managing an episode of severe or prolonged uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE AND IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In population-based studies, approximately 10 to 35 percent of women report having menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Menorrhagia is a common reason for referral to a gynecologist and 5 percent of women between the ages of 30 and 49 years consult a physician for evaluation of menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Iron deficiency anemia develops in 21 to 67 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. Excessive and irregular bleeding can detract from quality of life. Absenteeism from work or school is bothersome to many women and bleeding may also interfere with sexual activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy (&gt;80 ml) or prolonged (&gt;7 days) uterine bleeding is a symptom of a variety of abnormalities. The frequency of each etiology varies according to the patient's age group.",
"   </p>",
"   <p>",
"    Abnormal uterine bleeding in premenopausal adults is reviewed here. Abnormal uterine bleeding in adolescents and postmenopausal women is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"     \"Postmenopausal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reproductive age women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulation is common among reproductive age women and this condition is often accompanied by heavy or prolonged uterine bleeding. In reproductive age women with regular periods (suggesting ovulatory cycles), heavy or prolonged uterine bleeding is usually due to distortion of the endometrial architecture. Uterine leiomyomas are the most common pelvic tumor in women and are a common cause of excessive bleeding. Other common causes include endometrial polyps, adenomyosis, or presence of a non-progestin intrauterine device [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Thyroid disorders are another common etiology of uterine bleeding abnormalities. For adolescents, anovulation and bleeding diatheses are likely more common causes of heavy bleeding than structural abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=see_link\">",
"     \"Differential diagnosis and approach to the adolescent with abnormal uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Menopausal transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the menopausal transition, women can also have heavy or prolonged bleeding due to uterine structural abnormalities. In addition, endocrine abnormalities commonly contribute to abnormal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this group, intermittent anovulation often occurs and results in extended periods of estrogen production unopposed by progesterone, resulting in continued proliferation of the endometrium. The thickened endometrium eventually outgrows its blood supply and undergoes focal necrosis with partial shedding. Since progesterone and prostaglandin related changes have not occurred and shedding is not uniform, bleeding is usually irregular, prolonged, and heavy. Endometrial hyperplasia or cancer may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal ovulation is another common endocrine pattern observed in women during the menopausal transition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. This results from the maturation of multiple follicles, which yield abnormally high follicular estradiol levels. The follicular phase is shortened and abnormal ovulation occurs while menstrual shedding is still in process. This is followed by subnormal progesterone secretion in the luteal phase, producing an ovulatory cycle, but with a markedly increased estradiol to progesterone ratio.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps for evaluation of a woman who complains of chronic heavy or prolonged bleeding from the vagina are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirm a uterine source of bleeding on physical examination (",
"      <a class=\"graphic graphic_table graphicRef74527 \" href=\"UTD.htm?25/45/26334\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Perform a pregnancy test.",
"     </li>",
"     <li>",
"      Assess whether the woman is pre- or postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"       \"Clinical manifestations and diagnosis of menopause\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluate the pattern, volume, and duration of blood loss (",
"      <a class=\"graphic graphic_table graphicRef69390 \" href=\"UTD.htm?14/2/14379\">",
"       table 2",
"      </a>",
"      ); ovulation can generally be documented clinically, based on regular cyclic menses with molimina (eg, breast tenderness, bloating or pelvic discomfort, mood changes, thin vaginal discharge). Alternatively, ovulation can be confirmed by a serum progesterone level measured in the presumed luteal phase of the menstrual cycle; in most laboratories, a level of &gt;4",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      confirms ovulation.",
"     </li>",
"     <li>",
"      Perform laboratory testing for anemia; test for coagulopathy if anemia is diagnosed and if clinically indicated (eg, history of easy bruising or bleeding from mucosal surfaces, personal or family history of coagulopathy). The likelihood of finding a coagulopathy in an adult woman with menorrhagia is greatest in women with severe anemia (hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Perform pelvic sonography to assess for uterine or other reproductive tract abnormalities that may contribute to uterine bleeding.",
"     </li>",
"     <li>",
"      Sample the endometrium to exclude endometrial neoplasia or endometritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An endometrial biopsy should be performed in all women age 45 years or older with abnormal uterine bleeding to rule out endometrial cancer or a premalignant lesion (endometrial hyperplasia) (",
"    <a class=\"graphic graphic_table graphicRef58600 \" href=\"UTD.htm?18/38/19052\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/17\">",
"     17",
"    </a>",
"    ]. We also perform an endometrial biopsy in women &lt;45 years who have abnormal uterine bleeding that is persistent, occurs in the setting of a history of unopposed estrogen exposure (obesity, chronic anovulation) or failed medical management of the bleeding, or in women at high risk of endometrial cancer (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy, Lynch syndrome) (",
"    <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"     table 4",
"    </a>",
"    ). In addition, endometrial neoplasia should be suspected in premenopausal women who are anovulatory and have prolonged periods of amenorrhea (six or more months). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of women with abnormal uterine bleeding is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link&amp;anchor=H13#H13\">",
"     \"Terminology and evaluation of abnormal uterine bleeding in premenopausal women\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REFERRAL TO A GYNECOLOGIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the woman's primary care clinician is not comfortable performing endometrial sampling or placing an intrauterine device, the patient should be referred to a gynecologist. Referral to a gynecologist is also appropriate for women who have persistent bleeding despite treatment or require surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH TO MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment of underlying conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of certain underlying conditions before initiating other therapy may correct the bleeding or make further treatment more effective.",
"   </p>",
"   <p>",
"    These conditions include structural lesions that can either be treated in an office setting or are unlikely to respond to hormonal therapy (eg, small leiomyoma prolapsed through the cervix, endometrial polyps, arteriovenous malformation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link&amp;anchor=H5#H5\">",
"     \"Interventional radiology in management of gynecological disorders\", section on 'Arteriovenous malformation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H432924#H432924\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Myolysis'",
"    </a>",
"    .) In addition, women with suspected chronic endometritis (eg, recent childbirth or intrauterine procedure) can often be treated with a course of antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=see_link\">",
"     \"Endometritis unrelated to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some etiologies of anovulatory bleeding (eg, hypothyroidism) can be treated to restore regular ovulatory cycles, whereas others (eg, polycystic ovarian syndrome) are best treated to regulate bleeding episodes and prevent endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bleeding diatheses should also be controlled prior to initiating other therapy. Most bleeding diatheses can be treated medically to reduce menstrual blood loss; options include administration of a hemostatic agent or one of the nonspecific therapies described below [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of von Willebrand disease\", section on 'Treatment of excessive menstrual bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Choosing an initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choosing a management plan for chronic heavy or prolonged uterine bleeding in a premenopausal woman (after malignancy has been ruled out) is based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Etiology and severity of bleeding (eg, anemia, interference with daily activities)",
"     </li>",
"     <li>",
"      Associated symptoms (eg, pelvic pain, infertility)",
"     </li>",
"     <li>",
"      Contraceptive needs or plans for future pregnancy",
"     </li>",
"     <li>",
"      Contraindications to hormonal or other medications",
"     </li>",
"     <li>",
"      Medical comorbidities",
"     </li>",
"     <li>",
"      Patient preferences regarding medical versus surgical and short-term versus long-term therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medical therapy is the initial treatment approach for most women with heavy or prolonged uterine bleeding. This section provides an overview of treatment choices for specific patient populations. Data regarding the efficacy of individual treatments are discussed below (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Medical therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Women who are not anemic and are not at risk for endometrial neoplasia (ie, anovulatory cycles is a risk factor for endometrial neoplasia) may also reasonably choose expectant management. Depending on the volume of bleeding, we check a hematocrit every 6 to 12 months in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Women with anovulatory cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with anovulatory bleeding, either estrogen-progestin contraceptives, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    intrauterine device (LNG-IUD), or other progestin therapy decrease the risk of endometrial hyperplasia or cancer. Although the LNG-IUD does not regulate cycles, this is not a significant disadvantage, since most women will eventually become amenorrheic or have only scant bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Women with pelvic pain or pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with adenomyosis or leiomyomas may present with heavy or prolonged bleeding in combination with pelvic pain or pressure. The optimal approach in these patients is to address both issues with one type of treatment.",
"   </p>",
"   <p>",
"    For women with adenomyosis, hormonal treatments that inhibit ovulation generally ameliorate both pain and bleeding; the LNG-IUD or nonsteroidal antiinflammatory drugs (NSAIDs) are other useful options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with fibroids may experience symptoms due to pressure on surrounding viscera, including abdominal or pelvic discomfort, urinary frequency, or constipation. Only treatments that remove or reduce the size of the leiomyomas can simultaneously treat both the pressure and bleeding symptoms. These treatments include gonadotropin-releasing hormone agonists, uterine fibroid embolization, myomectomy, and hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Women planning pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When counseling a woman regarding treatment of chronic heavy or prolonged uterine bleeding, it is important to ask whether she would like to preserve her fertility and whether she is currently trying to conceive a pregnancy. Most treatment options do not interfere with fertility, however, endometrial ablation, uterine fibroid embolization, and hysterectomy preclude future pregnancy. Patients considering myomectomy should be counseled that this may commit them to cesarean delivery for subsequent pregnancies. In addition, use of the LNG-IUD is not cost-effective in women who are planning to conceive a pregnancy within the upcoming year.",
"   </p>",
"   <p>",
"    Treatment of women with chronic heavy or prolonged bleeding who are trying to conceive a pregnancy is challenging. The best option is oral progestin therapy. We use micronized progesterone (Prometrium) in these women rather than synthetic progestins, since there are conflicting data regarding whether medroxyprogesterone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    are teratogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/23\">",
"     23",
"    </a>",
"    ]. Other hormonal therapies interfere with ovulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conception. Non-hormonal options include NSAIDs and antifibrinolytic agents. NSAIDs should be stopped upon conception, since they are associated with miscarriage and congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    should be used only as a last resort, since they appear to be safe during pregnancy based on animal studies, but data in humans are lacking. Also, animal studies suggest that tranexamic acid interferes with ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H22\">",
"     'Antifibrinolytic agents'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Women with risk factors for thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with abnormal uterine bleeding who are at an increased risk of thrombosis require a nonestrogenic therapy;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    may also be contraindicated in these women. This includes women with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of arterial or venous thrombosis (eg, deep vein thrombosis)",
"     </li>",
"     <li>",
"      Medical conditions that predispose to thrombosis (eg, diabetes, inherited thrombophilia)",
"     </li>",
"     <li>",
"      Cigarette smoking in women &ge;35 years old &nbsp;",
"     </li>",
"     <li>",
"      NSAIDs or surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some progestin-only medications may be used. However, some progestins are prothrombotic.",
"   </p>",
"   <p>",
"    The thrombotic risks of estrogen-progestin and progestin-only contraceptives are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H7#H7\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Cardiovascular disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link&amp;anchor=H12#H12\">",
"     \"Progestin-only pills (minipills) for contraception\", section on 'Effect on cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10110271\">",
"    <span class=\"h3\">",
"     Women who are on anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant treatment is typically not the primary etiology of abnormal uterine bleeding, but may exacerbate it. Women who are on anticoagulant medications who have heavy, prolonged, or irregular uterine bleeding should be evaluated for the etiology and treated as appropriate. If pharmacologic management with prothrombotic medications is considered, this should be prescribed only after consultation with the physician managing the patient&rsquo;s anticoagulant therapy (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Women with risk factors for thrombosis'",
"    </a>",
"    above). Structural lesions (eg, endometrial polyps, uterine fibroids) may be removed with appropriate perioperative management of anticoagulation. For women on short-term anticoagulant therapy, medical management is preferable if bleeding associated with structural lesions is expected to resolve when the anticoagulation is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen-progestin contraceptives have traditionally been the first choice of therapy for most women with heavy or prolonged uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In addition to reducing blood flow, these agents regulate cycles, provide contraception, prevent the development of hyperplasia in anovulatory patients, and treat dysmenorrhea. An exception to use of this treatment is women with risk factors for thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of primary dysmenorrhea in adult women\", section on 'Hormonal contraception'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    intrauterine device (LNG-IUD) is also an effective option for many women, although it requires a procedure for placement and the reduction in bleeding may not be apparent until after three months of treatment. Women who choose this option typically prefer to avoid taking a medication daily, are comfortable with the presence of an intrauterine device, and are monogamous. Over the long-term, estrogen-progestin contraceptives are more costly than the LNG-IUD. In this article, LNG-IUD will refer to Mirena, which had been the only progestin IUD in the United States since it was introduced in 2000. In 2013, a lower dose progestin IUD, Skyla, was introduced, but this has not yet been studied for use in women with menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of intrauterine contraception\", section on 'Types of IUDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with regular cycles and dysmenorrhea, but who do not need contraception, nonsteroidal antiinflammatory drugs (NSAIDs) are preferred over estrogen-progestin contraceptives since they have fewer potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     First line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For initial therapy in most women, we suggest estrogen-progestin contraceptives rather than other medical therapies. Oral contraceptives are the type of estrogen-progestin contraceptives that have been used most commonly and studied most extensively, but other versions likely have similar efficacy (ie, ring, patch). Estrogen-progestin contraceptives are preferable to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing intrauterine device (LNG-IUD) as first line therapy because initiating the IUD requires a procedure and a substantial expense. The cost-effectiveness of the IUD compared with estrogen-progestin contraceptives depends upon the length of use.",
"   </p>",
"   <p>",
"    For women with contraindications to estrogen therapy, we suggest the LNG-IUD rather than other medical therapies. The LNG-IUD is also a reasonable alternative to estrogen-progestin contraceptives in women who do not have dysmenorrhea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prefer to avoid taking a daily medication and will likely require long-term treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Estrogen-progestin contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral contraceptives (OCs) with 30 to 35 mcg ethinyl estradiol regulate bleeding patterns in significantly more women than placebo (47 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/26,30\">",
"     26,30",
"    </a>",
"    ] and result in a reduction in blood flow (43 percent) similar to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    (38 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    (49 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/28,31\">",
"     28,31",
"    </a>",
"    ], based upon randomized trials.",
"   </p>",
"   <p>",
"    In contrast, OCs appear to be less effective than the LNG-IUD at reducing blood loss in women with menorrhagia. This was illustrated in two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In the best designed trial, at 12-month follow-up, the LNG-IUD resulted in a significantly greater reduction in menstrual blood loss (as measured by the alkaline hematin method) than a 30 mcg",
"    <span class=\"nowrap\">",
"     estradiol/150",
"    </span>",
"    mcg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    pill (87 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, women in the LNG-IUD group compared with the OC group had fewer days per month in which menstrual flow precluded normal daily activities (two versus seven days).",
"   </p>",
"   <p>",
"    The study design, method for measuring uterine blood loss, and treatment period varied across these trials. More high quality data are needed to adequately compare the efficacy of estrogen-progestin contraceptives with other types of therapy.",
"   </p>",
"   <p>",
"    There are no data regarding whether control of uterine bleeding differs among types of estrogen-progestin contraceptives (pill, patch, ring); the choice of preparation depends upon a woman's preference regarding delivery site (oral, transdermal, vaginal) and regimen (daily, weekly, monthly) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/34\">",
"     34",
"    </a>",
"    ]. There are data demonstrating that bleeding patterns can be influenced by steroid dosages within pills, with those containing lower progestin levels relative to ethinyl estradiol levels more likely to be associated with intermenstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/35\">",
"     35",
"    </a>",
"    ]. Estrogen-progestin contraceptives may be prescribed in a cyclic (with a monthly withdrawal bleed) or continuous (no withdrawal bleed) regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estrogen-progestin contraceptives are contraindicated in women who are at risk for thrombosis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Women with risk factors for thrombosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H3033285#H3033285\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Levonorgestrel-IUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LNG-IUD reduces menstrual blood loss by 74 to 97 percent after one year of use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/36\">",
"     36",
"    </a>",
"    ] and is appropriate for women with bleeding disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Mirena was approved by the United States Food and Drug Administration (FDA) in 2009 for treatment of heavy menstrual bleeding in women who use the IUD for contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/39\">",
"     39",
"    </a>",
"    ]. Mirena releases 20 mcg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    per day and produces serum concentrations of progestin that do not inhibit ovulation in most women. The high local progestin concentration results in a thinning of the endometrium. Some women experience an increase in irregular or heaving bleeding during the first three months after placement of the LNG-IUD. After three months, the most common bleeding pattern in previously menorrhagic women is spotting, and after six months, the majority of patients have amenorrhea or oligomenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The LNG-IUD appears to be more effective than other medical treatments. Quality of life outcomes were evaluated in a randomized trial (n = 571) that assigned women with menorrhagia to the LNG-IUD (Mirena) or usual treatment (most were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , other treatments were combined estrogen-progestin, progestin alone, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/41\">",
"     41",
"    </a>",
"    ]. The outcome measure was a score based on effects on six domains of daily life. Women in the LNG-IUD group had significantly higher scores at six months and two years. Significantly more women in the LNG-IUD group continued treatment at two years (64 verus 38 percent); the most common reason for discontinuation was lack of effectiveness. The rate of adverse effects was low and was comparable for both groups. Participants in the study were at the upper age range of women of reproductive age (mean age 42 years), which may limit the generalizability of the results to younger women. &nbsp;",
"   </p>",
"   <p>",
"    Randomized trials have found that the LNG-IUD reduces blood loss to a greater extent than OCs (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Estrogen-progestin contraceptives'",
"    </a>",
"    above). The LNG-IUD has also been found to be as or more effective than oral or parenteral progestins in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. A trial in which 44 women with regular, heavy bleeding were randomized to three months of treatment with the LNG-IUD versus oral norethisterone (NET) (5 mg three times daily, cycle days 5 to 26) reported a reduction in menstrual blood loss from baseline was similar in the LNG-IUD and NET groups (103 versus 95 ml); significantly more women treated with the LNG-IUD than NET wished to continue with the treatment (76 versus 22 percent). Another trial assigned 132 women who were undergoing the menopausal transition and had menorrhagia to either the LNG-IUD, oral medroxyprogesterone (5 mg daily), or intramuscular depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (one 150 mg dose) and found significantly greater reduction in bleeding in the LNG-IUD versus other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LNG-IUD also appears to be superior to nonhormonal medical therapy. A randomized trial (n = 51) assigned women to six months of treatment with the LNG-IUD versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    (500 mg three times daily for the first four cycle days) and found that menstrual blood loss was significantly lower in the LNG-IUD group (5 versus 100 ml) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. Another comparative study reported that, after 12 months of therapy, the reduction in menstrual blood flow was significantly greater in women treated with the LNG-IUD (96 percent) versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/42/33440?source=see_link\">",
"     flurbiprofen",
"    </a>",
"    (21 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/36,47\">",
"     36,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of contraindications to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD, which are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral nonsteroidal antiinflammatory drugs (NSAIDs) reduce the volume of menstrual blood loss by 20 to 50 percent in most women with heavy uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/27\">",
"     27",
"    </a>",
"    ]. The mechanism of this effect is a reduction in the rate of prostaglandin (PGE2 and PGF2 alpha) synthesis in the endometrium, leading to vasoconstriction and reduced bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of nine randomized trials found that reduction in uterine bleeding was significantly greater in most trials with NSAIDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"     mefenamic acid",
"    </a>",
"    ) versus placebo, but less effective than the LNG-IUD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/50\">",
"     50",
"    </a>",
"    ]. There were no significant differences in effect between NSAIDs and OCs or oral luteal progestins. Ethamsylate, a prostaglandin synthesis inhibitor that also reduces platelet fragility, has been used in the United Kingdom for treatment of menorrhagia. It is not more effective than NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/51\">",
"     51",
"    </a>",
"    ]. This analysis was limited by the small number of participants in each trial; also, several comparisons were made based upon a single trial.",
"   </p>",
"   <p>",
"    The advantages of NSAIDs are low cost, acceptable side effects, and reduction of dysmenorrhea. Unlike hormonal therapies, they do not need to be taken daily.",
"   </p>",
"   <p>",
"    NSAIDs used for treatment of chronic heavy or prolonged uterine bleeding are prescribed to start on the first day of menses and are discontinued either after five days or at the end of menses. Regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/63/41976?source=see_link\">",
"       Mefenamic acid",
"      </a>",
"      500 mg three times per day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/46,52\">",
"       46,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       Naproxen",
"      </a>",
"      500 mg at onset and three to five hours later, then 250 to 500 mg twice a day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/28,53,54\">",
"       28,53,54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      600 mg once per day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options other than first line treatments are either less effective or have more adverse effects than first line treatments, but may be appropriate for some women. The side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    and gonadotropin-releasing hormone agonists make them less acceptable than other drugs for long-term use. Luteal phase, low dose progestins are ineffective in ovulatory women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Antifibrinolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifibrinolytic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (1300 mg three times per day during menses for a maximum of five days) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    , reduce menstrual flow 30 to 55 percent from baseline and are more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. They only need to be taken on the days of menses and do not interfere with fertility.",
"   </p>",
"   <p>",
"    Antifibrinolytic drugs are more effective than NSAIDs and luteal phase progestins in reducing heavy menstrual bleeding. They appear to be less effective than the LNG-IUD, as discussed above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Levonorgestrel-IUD'",
"    </a>",
"    above). They are more costly than NSAIDs and oral progestins.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     Tranexamic acid",
"    </a>",
"    was approved by the United States Food and Drug Association in 2009 for treatment of menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/59\">",
"     59",
"    </a>",
"    ]. The risk of thrombotic events with antifibrinolytic agents is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=see_link&amp;anchor=H27#H27\">",
"     \"Managing an episode of severe or prolonged uterine bleeding\", section on 'Tranexamic acid'",
"    </a>",
"    .) We use these agents only when other options have been unsuccessful and only in women who are not at a high risk of thrombosis. These agents therefore have limited use in women with contraindications to hormonal therapy, since they increase the risk of thrombosis. Gastrointestinal discomfort, leg cramps, dizziness, headaches, and allergic reactions are minor side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Oral or parenteral progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral or parenteral progestin therapy is used for prevention of excessive bleeding related to endometrial hyperplasia in women with chronic anovulation, but is less effective than the LNG-IUD (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Levonorgestrel-IUD'",
"    </a>",
"    above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low dose luteal phase progestins (administered from cycle days 15 to 26) should not be used for ovulatory women, since this treatment was significantly less effective than other therapies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    , progesterone-releasing intrauterine contraception) in a systematic review of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Gonadotropin-releasing hormone agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;GnRH analogs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    ) induce a menopausal state in premenopausal women that leads to amenorrhea. One-third of ovulatory patients with menorrhagia become amenorrheic after three treatment cycles with a GnRH agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/57\">",
"     57",
"    </a>",
"    ]. There are, however, a number of disadvantages that limit the use of these drugs for the treatment of chronic menorrhagia. These include high cost, the need for estrogen or progestin add-back therapy if used for more than three to six months to prevent osteopenia, and the return of menstrual blood loss to pretreatment levels when the drug is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=see_link&amp;anchor=H207353414#H207353414\">",
"     \"Gonadotropin releasing hormone agonists for long-term treatment of endometriosis\", section on 'GnRH with add-back therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GnRH antagonists are currently not approved by the United States Food and Drug Association for the indication of treatment of abnormal uterine bleeding and are not commonly used for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Danazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral administration of androgenic steroids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    (200 to 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    reduces heavy bleeding from chronic menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/18,62\">",
"     18,62",
"    </a>",
"    ] and appears to be more effective than placebo, NSAIDs, progestins, or OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/63\">",
"     63",
"    </a>",
"    ]. However, data are limited to a few trials with a small number of subjects. Danazol is costly and unacceptable side effects occur in approximately 40 percent of patients. Therefore, it is not used as one of the standard treatments of chronic heavy or prolonged uterine bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial ablation is a minimally invasive option for treatment of heavy or prolonged uterine bleeding when medical therapy fails or in women who do not want to use chronic medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/64-72\">",
"     64-72",
"    </a>",
"    ]. Pregnancy is contraindicated after endometrial ablation, but contraception is still required. Endometrial ablation is as effective as the LNG-IUD in reducing menstrual blood flow (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Levonorgestrel-IUD'",
"    </a>",
"    above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"     \"An overview of endometrial ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endometrial resection, a type of ablation, was compared with medical therapy in a randomized trial that assigned 187 women with heavy menstrual bleeding to endometrial resection or oral medication (at least three cycles, specific medication varied) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/68\">",
"     68",
"    </a>",
"    ]. At four-month follow-up, days of heavy bleeding were significantly reduced in women treated with endometrial resection versus medication (0.8 versus 3.2 days). At five-year follow-up, the rate of hysterectomy was similar in women initially randomized to resection or medical therapy (18 and 19 percent); among women in the original medical therapy group, 10 percent still used medical treatment and 59 percent had surgical treatment other than hysterectomy. Further high quality data are needed to compare medical therapy with global endometrial ablation methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is the definitive treatment for uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/70\">",
"     70",
"    </a>",
"    ]. This procedure has a high rate of patient satisfaction because it is curative, is frequently performed after medical management has failed, is not associated with drug-related side effects, and does not require repeated procedures or prolonged follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/69,70,73,74\">",
"     69,70,73,74",
"    </a>",
"    ]. On the other hand, hysterectomy has a risk of perioperative complications and, depending on the operative approach, a prolonged recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link\">",
"     \"Overview of hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other surgical options for women with leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with leiomyomas can also be treated with fibroid-specific minimally invasive procedures (eg, hysteroscopic myomectomy, uterine artery embolization) or major surgery (abdominal myomectomy). Treatment of leiomyomas is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CHOOSING A LONG-TERM TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of heavy or prolonged bleeding may persist for years. The goal of initial therapy is to control the bleeding, treat anemia (if present), and restore quality of life. Once this has been accomplished, some women are satisfied with continuing chronic medical therapy, while others desire a treatment that requires less maintenance or is definitive.",
"   </p>",
"   <p>",
"    Minimally invasive procedures to control heavy uterine bleeding include the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    IUD (LNG-IUD) and endometrial ablation. Hysterectomy is generally reserved for women who fail all other measures; however, women who desire definitive treatment and are aware of other treatment options and surgical risk may also reasonably choose hysterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Medical versus surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women often choose surgical therapy after long-term medical therapy. A systematic review of eight randomized trials of women with heavy menstrual bleeding found that 58 percent of women randomly assigned to medical treatment underwent surgery by two years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one trial randomized 63 women with persistent abnormal uterine bleeding (median duration four years) who were dissatisfied with medroxyprogesterone treatment to undergo hysterectomy (route per provider) or expanded medical therapy, primarily with cyclic OCs and a NSAID (alternative estrogen-progestin regimens were also employed) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. By 18 months, 53 percent of women in the medical treatment group had asked for and received a hysterectomy (median interval to crossing over was six months). At two years, mean resource use in the medicine and hysterectomy arms were $4479 and $6777, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/78\">",
"     78",
"    </a>",
"    ]. Broken down to resource use by treatment actually received, the costs for medicine only, medicine followed by hysterectomy, and hysterectomy only were $2595, $6128, and $7024, respectively.",
"   </p>",
"   <p>",
"    The choice of surgery may be based upon avoidance of medication-related side effects. In the systematic review, at four-month follow-up, endometrial resection compared with oral medication was significantly more effective in controlling bleeding (OR 10.6, 95% CI 5.3 to 21.3) and significantly less likely to cause side effects (OR 0.2, 95% CI 0.1 to 0.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/75\">",
"     75",
"    </a>",
"    ]. Hysterectomy resulted in significantly greater improvements in mental health at six-month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Levonorgestrel-IUD versus surgical treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cost-utility model study from Hong Kong reported that over a period of five years, treatment with the LNG-IUD compared with oral medical treatment, endometrial ablation, or hysterectomy was less expensive and accrued more quality adjusted life years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/79\">",
"     79",
"    </a>",
"    ]. It is important to note that cost-utility calculations may vary in different health care settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who wish to stop using chronic medical therapy or have contraindications to medications, minimally invasive options include the LNG-IUD or endometrial ablation. A systematic review of six randomized trials and a subsequent randomized trial found that women with menorrhagia who were treated with either the LNG-IUD or endometrial ablation had similar reductions in menstrual blood loss at 6, 12, and 24 months, as well as similar improvements in quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. A meta-analysis of four randomized trials found that rates of dissatisfaction were similar for women treated with the LNG-IUD (17 percent) compared with endometrial ablation (18 percent) (OR 0.9, 95% CI 0.5-1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/82\">",
"     82",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The decision to use the LNG-IUD or endometrial ablation depends upon a patient's preferences regarding treatment factors such as plans for fertility and contraception, convenience, and risks of anesthesia. The LNG-IUD is a reversible contraceptive. Pregnancy is contraindicated after endometrial ablation, but the procedure does not prevent pregnancy; thus, women will need to continue to use contraception following ablation. The LNG-IUD can be placed in an office setting for all women and requires no or local anesthesia. Endometrial ablation can also be done in an office by surgeons who are appropriately equipped, but is often performed in an operating room under general anesthesia. If successful, endometrial ablation is performed once, while the LNG-IUD needs to be replaced every five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health-related quality of life is similar for women treated with either the LNG-IUD or hysterectomy, according to a meta-analysis of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LNG-IUD was compared with hysterectomy in a randomized trial of 236 women with menorrhagia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Health-related quality of life improved equally in both groups at one and five years; placement of the IUD was more cost-effective than surgery. However, after one year, a third of the women had the devices removed and 20 percent underwent hysterectomy; after five years, 40 percent underwent hysterectomy.",
"   </p>",
"   <p>",
"    On the other hand, 10-year follow-up from a randomized trial in which 236 women were treated with either hysterectomy or LNG-IUD reported that women in the IUD group had significantly lower rates of stress urinary incontinence (34 versus 48 percent) and usage of medications for urinary incontinence (1 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another randomized trial compared treatment with hysterectomy versus LNG-IUD. Improvements in quality of life were equal in both groups; however, 40 percent of women in the LNG-IUD group ultimately underwent hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Despite the high frequency of cross-over to surgical therapy, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD group had substantially lower total costs ($2817 versus 4660 per participant).",
"   </p>",
"   <p>",
"    Trials with more selective inclusion criteria may better define the optimal choice of therapy. As an example, two-thirds of women in the first trial had uterine leiomyomas, for which medical treatment with OCs, progestational agents, and nonsteroidal antiinflammatory drugs may be ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Endometrial ablation versus hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with hysterectomy, a systematic review of randomized trials found that endometrial ablation was associated with a shorter duration of surgery, hospital stay, time to return to usual activities, and fewer complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/41/20122/abstract/70\">",
"     70",
"    </a>",
"    ]. However, hysterectomy provided significantly better control of bleeding, a lower rate of repeat surgery, and improved patient satisfaction at follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H47#H47\">",
"     \"An overview of endometrial ablation\", section on 'Endometrial ablation versus other treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       \"Patient information: Heavy periods (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"       \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"       \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menorrhagia refers to menstrual blood loss greater than 80 mL. Heavy or prolonged uterine bleeding may occur in women with ovulatory or anovulatory cycles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of menorrhagia should be tailored to treat the underlying cause, correct associated problems (anemia), and, when possible, prevent recurrences, while taking into consideration the patient's contraception needs and plans for future childbearing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial approach to management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For first line treatment of premenopausal women with heavy or prolonged uterine bleeding, we suggest medical therapy over surgical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing an initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial therapy in most women, we suggest estrogen-progestin contraceptives rather than other medical therapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women with contraindications to estrogen therapy, we suggest the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      -releasing intrauterine device (LNG-IUD) rather than other medical therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The LNG-IUD is also a reasonable alternative to estrogen-progestin contraceptives in women who do not have dysmenorrhea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prefer to avoid taking a daily medication. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing an initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-steroidal antiinflammatory drugs are an option for women in whom hormonal contraceptive agents are contraindicated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      who do not require contraception, particularly those with dysmenorrhea. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Choosing an initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antifibrinolytic agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       tranexamic acid",
"      </a>",
"      may be more effective than non-steroidal antiinflammatory agents but less effective than LNG-IUD. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Antifibrinolytic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with anovulatory cycles require therapy that includes a progestin (ie, progestins alone or combined estrogen-progestin). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Women with anovulatory cycles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endometrial ablation and hysterectomy preclude subsequent pregnancy. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For long-term therapy in most women, we suggest the LNG-IUD rather than other medical therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also suggest the LNG-IUD rather than endometrial ablation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endometrial ablation is a reasonable choice in women who do not desire future pregnancy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wish to avoid using or changing an intrauterine device. Hysterectomy is a reasonable option in women who desire definitive therapy and who are aware of the risk of perioperative complications. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Choosing a long-term treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Levonorgestrel-IUD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysterectomy is the definitive therapy for menorrhagia. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Hysterectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/1\">",
"      Cole SK, Billewicz WZ, Thomson AM. Sources of variation in menstrual blood loss. J Obstet Gynaecol Br Commonw 1971; 78:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/2\">",
"      Hallberg L, H&ouml;gdahl AM, Nilsson L, Rybo G. Menstrual blood loss--a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/3\">",
"      Woolcock JG, Critchley HO, Munro MG, et al. Review of the confusion in current and historical terminology and definitions for disturbances of menstrual bleeding. Fertil Steril 2008; 90:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/4\">",
"      C&ocirc;t&eacute; I, Jacobs P, Cumming DC. Use of health services associated with increased menstrual loss in the United States. Am J Obstet Gynecol 2003; 188:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/5\">",
"      Santer M, Warner P, Wyke S. A Scottish postal survey suggested that the prevailing clinical preoccupation with heavy periods does not reflect the epidemiology of reported symptoms and problems. J Clin Epidemiol 2005; 58:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/6\">",
"      Shapley M, Jordan K, Croft PR. An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 2004; 54:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/7\">",
"      Warner P, Critchley HO, Lumsden MA, et al. Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management. BMJ 2001; 323:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/8\">",
"      Vessey MP, Villard-Mackintosh L, McPherson K, et al. The epidemiology of hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol 1992; 99:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/9\">",
"      Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/10\">",
"      Milman N, Clausen J, Byg KE. Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 1998; 77:13.",
"     </a>",
"    </li>",
"    <li>",
"     Rybo, G, Leman, J, Tibblin, R. Epidemiology of menstrual blood loss. In: Mechanisms of menstrual bleeding. Baird, DT, Michie, EA (eds). Raven Press, New York 1985. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/12\">",
"      Fraser IS, McCarron G, Markham R, et al. Measured menstrual blood loss in women with menorrhagia associated with pelvic disease or coagulation disorder. Obstet Gynecol 1986; 68:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/13\">",
"      Hale GE, Manconi F, Luscombe G, Fraser IS. Quantitative measurements of menstrual blood loss in ovulatory and anovulatory cycles in middle- and late-reproductive age and the menopausal transition. Obstet Gynecol 2010; 115:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/14\">",
"      Eisenhofer G. Editorial: biochemical diagnosis of pheochromocytoma--is it time to switch to plasma-free metanephrines? J Clin Endocrinol Metab 2003; 88:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/15\">",
"      Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996; 81:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/16\">",
"      Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod 2002; 17:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/17\">",
"      Committee on Practice Bulletins&mdash;Gynecology. Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol 2012; 120:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/18\">",
"      Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol 1996; 175:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/19\">",
"      Doherty L, Harper A, Russell M. Menorrhagia management options. Ulster Med J 1995; 64:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/20\">",
"      Duckitt K, Shaw RW. Is medical management of menorrhagia obsolete? Br J Obstet Gynaecol 1998; 105:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/21\">",
"      Fender GR, Prentice A, Gorst T, et al. Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ 1999; 318:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/22\">",
"      Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006; 95:75.",
"     </a>",
"    </li>",
"    <li>",
"     www.reprotox.org (Accessed December 23, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/24\">",
"      Yoshimura Y, Santulli R, Atlas SJ, et al. The effects of proteolytic enzymes on in vitro ovulation in the rabbit. Am J Obstet Gynecol 1987; 157:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/25\">",
"      Kaufman G, Dharmarajan AM, Takehara Y, et al. The role of protein kinase-C in gonadotropin-induced ovulation in the in vitro perfused rabbit ovary. Endocrinology 1992; 131:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/26\">",
"      Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000; 96:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/27\">",
"      Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf 2004; 27:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/28\">",
"      Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991; 31:66.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.multivu.com/mnr/58310-u-s-fda-approves-skyla-for-prevention-of-pregnancy-for-up-to-three-years (Accessed on January 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/30\">",
"      Jensen JT, Parke S, Mellinger U, et al. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011; 117:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/31\">",
"      Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009; :CD000154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/32\">",
"      Endrikat J, Shapiro H, Lukkari-Lax E, et al. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 2009; 31:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/33\">",
"      Shaaban MM, Shabaan MM, Zakherah MS, et al. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial. Contraception 2011; 83:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/34\">",
"      ACOG Practice Bulletin No. 110: noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010; 115:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/35\">",
"      Saleh WA, Burkman RT, Zacur HA, et al. A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels. Am J Obstet Gynecol 1993; 168:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/36\">",
"      Stewart A, Cummins C, Gold L, et al. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 2001; 108:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/37\">",
"      Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004; 111:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/38\">",
"      Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 2005; 193:1361.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm184747.htm (Accessed December 27, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/40\">",
"      Monteiro I, Bahamondes L, Diaz J, et al. Therapeutic use of levonorgestrel-releasing intrauterine system in women with menorrhagia: a pilot study(1). Contraception 2002; 65:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/41\">",
"      Gupta J, Kai J, Middleton L, et al. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med 2013; 368:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/42\">",
"      K&uuml;&ccedil;&uuml;k T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008; 35:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/43\">",
"      Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/44\">",
"      Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005; :CD002126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/45\">",
"      Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/46\">",
"      Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005; 112:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/47\">",
"      Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/48\">",
"      Rees MC, DiMarzo V, Tippins JR, et al. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. J Endocrinol 1987; 113:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/49\">",
"      Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol 1981; 88:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/50\">",
"      Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007; :CD000400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/51\">",
"      Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/52\">",
"      van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential menorrhagia. Am J Obstet Gynecol 1992; 166:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/53\">",
"      Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986; 68:10.",
"     </a>",
"    </li>",
"    <li>",
"     Rybo, G, Nilsson, S, Sikstrom, B, Nygren, KG. Naproxen in menorrhagia (letter). Lancet 198; :608.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/55\">",
"      M&auml;k&auml;r&auml;inen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986; 93:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/56\">",
"      Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; :CD000249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/57\">",
"      Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/58\">",
"      Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116:865.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm190551.htm. (Accessed February 1, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/60\">",
"      Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008; :CD001016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/61\">",
"      Shaw RW, Fraser HM. Use of a superactive luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia. Br J Obstet Gynaecol 1984; 91:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/62\">",
"      Stabinsky SA, Einstein M, Breen JL. Modern treatments of menorrhagia attributable to dysfunctional uterine bleeding. Obstet Gynecol Surv 1999; 54:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/63\">",
"      Beaumont H, Augood C, Duckitt K, Lethaby A. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2007; :CD001017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/64\">",
"      Carlson KJ, Schiff I. Alternatives to hysterectomy for menorrhagia. N Engl J Med 1996; 335:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/65\">",
"      Stirrat GM. Choice of treatment for menorrhagia. Lancet 1999; 353:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/66\">",
"      O'Connor H, Magos A. Endometrial resection for the treatment of menorrhagia. N Engl J Med 1996; 335:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/67\">",
"      Unger JB, Meeks GR. Hysterectomy after endometrial ablation. Am J Obstet Gynecol 1996; 175:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/68\">",
"      Cooper KG, Jack SA, Parkin DE, Grant AM. Five-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. BJOG 2001; 108:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/69\">",
"      A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years. Aberdeen Endometrial Ablation Trials Group. Br J Obstet Gynaecol 1999; 106:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/70\">",
"      Lethaby A, Hickey M, Garry R, Penninx J. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2009; :CD001501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/71\">",
"      Lethaby A, Hickey M. Endometrial destruction techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2002; :CD001501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/72\">",
"      Hidlebaugh DA, Orr RK. Long-term economic evaluation of resectoscopic endometrial ablation versus hysterectomy for the treatment of menorrhagia. J Am Assoc Gynecol Laparosc 1998; 5:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/73\">",
"      Reich H, Ribeiro SC, Vidali A. Hysterectomy as treatment for dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/74\">",
"      Ballard L, Lyon DS, Jones JL. Inpatients with menometrorrhagia: etiologies, treatments, and outcomes. South Med J 2000; 93:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/75\">",
"      Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006; :CD003855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/76\">",
"      Kuppermann M, Varner RE, Summitt RL Jr, et al. Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA 2004; 291:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/77\">",
"      Learman LA, Summitt RL Jr, Varner RE, et al. Hysterectomy versus expanded medical treatment for abnormal uterine bleeding: clinical outcomes in the medicine or surgery trial. Obstet Gynecol 2004; 103:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/78\">",
"      Showstack J, Lin F, Learman LA, et al. Randomized trial of medical treatment versus hysterectomy for abnormal uterine bleeding: resource use in the Medicine or Surgery (Ms) trial. Am J Obstet Gynecol 2006; 194:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/79\">",
"      You JH, Sahota DS, MoYuen P. A cost-utility analysis of hysterectomy, endometrial resection and ablation and medical therapy for menorrhagia. Hum Reprod 2006; 21:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/80\">",
"      Kaunitz AM, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009; 113:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/81\">",
"      de Souza SS, Camargos AF, de Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleeding. Contraception 2010; 81:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/82\">",
"      Middleton LJ, Champaneria R, Daniels JP, et al. Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients. BMJ 2010; 341:c3929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/83\">",
"      Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/84\">",
"      Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004; 291:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/41/20122/abstract/85\">",
"      Heli&ouml;vaara-Peippo S, Halmesm&auml;ki K, Hurskainen R, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial. BJOG 2010; 117:602.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5476 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20122=[""].join("\n");
var outline_f19_41_20122=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE AND IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reproductive age women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Menopausal transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REFERRAL TO A GYNECOLOGIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment of underlying conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Choosing an initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Women with anovulatory cycles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Women with pelvic pain or pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Women planning pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Women with risk factors for thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10110271\">",
"      - Women who are on anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      First line therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Levonorgestrel-IUD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Antifibrinolytic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Oral or parenteral progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Gonadotropin-releasing hormone agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Danazol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other surgical options for women with leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CHOOSING A LONG-TERM TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Medical versus surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Levonorgestrel-IUD versus surgical treatments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Endometrial ablation versus hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5476|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/45/26334\" title=\"table 1\">",
"      Causes genital tract bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14379\" title=\"table 2\">",
"      Assessing menstrual blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/38/19052\" title=\"table 3\">",
"      Indications endometrial evaluat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39403\" title=\"table 4\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11160?source=related_link\">",
"      Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/1/17431?source=related_link\">",
"      Endometritis unrelated to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8761?source=related_link\">",
"      Gonadotropin releasing hormone agonists for long-term treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=related_link\">",
"      Managing an episode of severe or prolonged uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=related_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=related_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_41_20123="Androgens in PCOS";
var content_f19_41_20123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of serum androgens in women with PCOS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Androgen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ovary",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adrenal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peripheral conversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DHEA-S",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        &gt;95",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Androstenedione (A)",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        5 (from DHEA-S)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testosterone (T)",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        35 (from A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dihydrotestosterone (DHT)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        100 (from A and T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-Androstanediol glucuronide",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        100 (from DHT)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Values are percent of total production at the different sites.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20123=[""].join("\n");
var outline_f19_41_20123=null;
var title_f19_41_20124="Spectrum of hepatotoxicity";
var content_f19_41_20124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of drug-induced hepatotoxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Subclinical",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sulfonamides, salicylates, sulfonylureas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Acute hepatic injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytotoxic (acetaminophen)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Steatosis (amiodarone; AZT, ddI)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cholestatic (bactrim, rifampin)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Extrahepatic (penicillin, sulfa)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chronic cholestasis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intrahepatic cholestasis (bactrim)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Biliary sclerosis (floxuridine)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Granulomatous disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Amiodarone, sulfonamides, isoniazid",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chronic hepatic injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chronic active hepatitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Steatosis (steroids, MTX, EtOH)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Phospholipidosis (amiodarone)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Fibrosis/cirrhosis (AZA, OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Vascular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hepatic vein thrombosis (OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          SOS (herbs, OCPs, chemoTx)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Peliosis hepatis (AZA, OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neoplasia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adenoma (OCPs)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          HCC (aflatoxin, alcohol)",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MTX: methotrexate; AZA: azathioprine; OCP: oral contraceptives pills; chemoTx: chemotherapy; SOS: sinusoidal obstruction syndrome (veno-occlusive disease); HCC: hepatocellular carcinoma.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20124=[""].join("\n");
var outline_f19_41_20124=null;
var title_f19_41_20125="Types of bradykinin-mediated angioedema";
var content_f19_41_20125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of bradykinin-mediated angioedema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 178px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Differential diagnosis of bradykinin-mediated angioedema.",
"    <div class=\"footnotes\">",
"     ACE: angiotensin-converting enzyme; HAE: hereditary angioedema.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 2012; 12:72. Copyright &copy; 2012; with kind permission from Springer Science + Business Media B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20125=[""].join("\n");
var outline_f19_41_20125=null;
var title_f19_41_20126="Probability of incomplete pulmonary nodule resection";
var content_f19_41_20126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Probability of incomplete resection according to number of pulmonary nodules on preoperative computed tomography (CT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 358px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Filled circles are actual probabilities, and the solid line (enclosed within dashed 68 percent confidence limits) is the logistic regression estimate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murthy, SC, Kim, K, Rice, TW, et al. Can we predict long-term survival after pulmonary metastatectomy for renal cell carcinoma? Ann Thorac Surg 2005; 79:996. Copyright &copy;2005 Society of Thoracic Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20126=[""].join("\n");
var outline_f19_41_20126=null;
var title_f19_41_20127="Maintenance agents for lung transplant";
var content_f19_41_20127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents for maintenance of immunosuppression following lung transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug monitoring",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolism/transporter effects with selected drug interactions",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common major adverse&nbsp;effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylprednisolone, prednisone",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits humoral and cell-mediated immunity",
"        </p>",
"        <p>",
"         Binds with DNA sequences (+/- nuclear factor-kB) to inhibit production of inflammatory cytokines",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         At time of transplant: 1 gram methylprednisolone intravenously",
"        </p>",
"        <p>",
"         Maintenance oral prednisone dose: 0.5 to 1 mg/kg per day initially after transplant with taper to a goal of 5 to 10 mg per day over several months to one year",
"        </p>",
"        <p>",
"         Protocols may vary by institution",
"        </p>",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        <p>",
"         Cytochrome P450 3A4 substrate",
"        </p>",
"        <p>",
"         Numerous clinically relevant interactions in transplant patients",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Diabetes",
"        </p>",
"        <p>",
"         GERD, PUD",
"        </p>",
"        <p>",
"         Osteoporosis",
"        </p>",
"        <p>",
"         Skeletal muscle wasting",
"        </p>",
"        <p>",
"         Hypertension",
"        </p>",
"        <p>",
"         Hypercholesterolemia",
"        </p>",
"        <p>",
"         Change in appetite",
"        </p>",
"        <p>",
"         Weight gain",
"        </p>",
"       </td>",
"       <td>",
"        Do not stop abruptly; may be taken with food to reduce dyspepsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Calcineurin inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclosporine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Prevents T cell activation and proliferation by inhibiting the production of interleukins and other cytokines",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         2 to 3 mg/kg per day&nbsp;intravenously at time of transplantation given in a 24 hour infusion or 1 to 1.5 mg/kg in two 4 hour infusions and until patient can tolerate oral intake. Adjust dose to target trough concentration of 250 to 350 ng/mL and two hour post dose (C2) concentration of 900 to 1200 ng/mL",
"        </p>",
"        <p>",
"         Maintenance oral dose: 3 to 5 mg/kg twice per day 12 hours apart, adjusted according to trough or C2 concentraion as above",
"        </p>",
"       </td>",
"       <td>",
"        Trough levels typically used but levels drawn two hours post dose (C2)&nbsp;are most accurate",
"       </td>",
"       <td>",
"        <p>",
"         Metabolized by cytochrome P450 enzyme system",
"        </p>",
"        <p>",
"         Cytochrome P450 3A4 substrate/inhibitor, p-glycoprotein substrate/inhibitor",
"        </p>",
"        <p>",
"         Marked increase in levels of statin drugs when co-administered",
"        </p>",
"        <p>",
"         Numerous clinically relevant interactions in transplant patients",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Renal dysfunction including acute nephrotoxicity",
"        </p>",
"        <p>",
"         Hypertension",
"        </p>",
"        <p>",
"         Hypercholesterolemia",
"        </p>",
"        <p>",
"         Gingival hyperplasia",
"        </p>",
"        <p>",
"         Neurotoxicity (tremor, headache)",
"        </p>",
"        <p>",
"         Hirsutism",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         High inter- and intra-individual absorption variability",
"        </p>",
"        <p>",
"         Blood concentration monitoring is necessary for change in formulation (including switch between generics or brands) to determine need for dose alteration. The microemulsion form, which is also known as \"modified\" (Neoral",
"         <sup>",
"          &reg;",
"         </sup>",
"         ) is generally better absorbed than the non-modified form (Sandimmune",
"         <sup>",
"          &reg;",
"         </sup>",
"         )",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tacrolimus",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Prevents T cell activation and proliferation by inhibiting the production of interleukins and other cytokines",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         0.05 to 0.1 mg/kg over 24 hours&nbsp;intravenously at time of transplantation and until patient can tolerate oral intake",
"        </p>",
"        <p>",
"         Maintenance oral dose: 0.1 mg/kg twice daily taken 12 hours apart on an empty stomach or two hours after eating. Adjust dose to target concentration of 8 to 15 ng/mL",
"        </p>",
"       </td>",
"       <td>",
"        Trough levels are typically used",
"       </td>",
"       <td>",
"        <p>",
"         Metabolized by cytochrome P450 enzyme system",
"        </p>",
"        <p>",
"         Cytochrome P450 3A4 substrate",
"        </p>",
"        <p>",
"         Marked increase in levels of statin drugs when co-administered",
"        </p>",
"        <p>",
"         Numerous clinically relevant interactions in transplant patients",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Renal dysfunction",
"        </p>",
"        <p>",
"         Diabetes",
"        </p>",
"        <p>",
"         Hypertension (less than cyclosporine)",
"        </p>",
"        <p>",
"         Hypercholesterolemia",
"        </p>",
"        <p>",
"         Altered mental status",
"        </p>",
"        <p>",
"         Headache",
"        </p>",
"        <p>",
"         Focal neurological deficits",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         High inter- and intra-individual absorption variability",
"        </p>",
"        <p>",
"         Blood concentration monitoring is necessary for change in formulation (including switch between generics or brands) to determine need for dose alteration",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Antimetabolites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycophenolate mofetil (CellCept",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        <p>",
"         Nucleotide blocking agent",
"        </p>",
"        <p>",
"         Inhibits T cell proliferation by blocking nucleotide synthesis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         IV equivalent to oral",
"        </p>",
"        <p>",
"         Starting dose: 250 mg twice daily within 72 hours after transplantation",
"        </p>",
"        <p>",
"         Gradually increase dose by 250 mg twice daily to a goal dose of 500 to 1000 mg twice&nbsp;daily",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Monitor WBC",
"        </p>",
"        <p>",
"         Dose adjusted for leukopenia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Levels decreased by:",
"         <br/>",
"         - Magnesium",
"         <br/>",
"         - Aluminum hydroxide",
"         <br/>",
"         - Antacids",
"         <br/>",
"         - Cholestyramine",
"         <br/>",
"         - Cyclosporine (but not tacrolimus)",
"        </p>",
"        <p>",
"         Levels increased by:",
"         <br/>",
"         - Probenecid",
"         <br/>",
"         - Acyclovir",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nausea, vomiting, diarrhea, abdominal pain",
"        </p>",
"        <p>",
"         Myelosuppression",
"        </p>",
"        <p>",
"         Anemia",
"        </p>",
"        <p>",
"         Increased risk of CMV disease",
"        </p>",
"       </td>",
"       <td>",
"        May inactivate protein bound drugs, especially",
"        <strong>",
"         oral contraceptives",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycophenolate sodium, enteric coated (Myfortic",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        <p>",
"         Nucleotide blocking agent",
"        </p>",
"        <p>",
"         Inhibits T cell proliferation by blocking nucleotide synthesis",
"        </p>",
"       </td>",
"       <td>",
"        360 to 720 mg orally twice per day",
"       </td>",
"       <td>",
"        <p>",
"         Monitor WBC",
"        </p>",
"        <p>",
"         Dose adjusted for leukopenia&nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Levels decreased by:",
"         <br/>",
"         - Magnesium",
"         <br/>",
"         - Aluminum hydroxide",
"         <br/>",
"         - Antacids",
"         <br/>",
"         - Cholestyramine",
"         <br/>",
"         - Cyclosporine (but not tacrolimus)",
"        </p>",
"        <p>",
"         Levels increased by:",
"         <br/>",
"         - Probenecid",
"         <br/>",
"         - Acyclovir",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nausea, vomiting",
"        </p>",
"        <p>",
"         Diarrhea",
"        </p>",
"        <p>",
"         Myelosuppression, anemia",
"        </p>",
"        <p>",
"         Increased risk of CMV disease",
"        </p>",
"       </td>",
"       <td>",
"        May inactivate protein bound drugs, especially",
"        <strong>",
"         oral contraceptives",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azathioprine",
"       </td>",
"       <td>",
"        <p>",
"         Nucleotide blocking agent",
"        </p>",
"        <p>",
"         Inhibits T and B cell proliferation by blocking nucleotide synthesis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         IV equivalent to oral",
"        </p>",
"        <p>",
"         Starting dose: 1 to 2 mg/kg daily and adjusted to prevent development of leukopenia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Monitor WBC",
"        </p>",
"        <p>",
"         Dose adjusted for leukopenia",
"        </p>",
"        <p>",
"         Monitor LFTs",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Levels increased by:",
"         <br/>",
"         - Allopurinol (Prefereably avoid co-administration. If co-administration required, reduce azathioprine by up to 70 percent)",
"        </p>",
"        <p>",
"         May diminish anticoagulant effects of warfarin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nausea, vomiting",
"        </p>",
"        <p>",
"         Diarrhea",
"        </p>",
"        <p>",
"         Bone marrow suppression",
"        </p>",
"        <p>",
"         Liver abnormality",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Requires TPMT enzyme for metabolism. Individuals with profound initial side effects may be deficient in this enzyme",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        mTOR inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sirolimus",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits T cell proliferation by cell cycle arrest in G1 phase",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sirolimus is initiated three months post-transplantation, due to effects on wound healing",
"        </p>",
"        <p>",
"         Liquid and tablet form",
"        </p>",
"        <p>",
"         Starting dose: 2 mg orally per day and adjusted to maintain a trough target between 4 and 15 ng/mL in combination with cyclosporine",
"        </p>",
"        <p>",
"         Administer sirolimus 4 hours after cyclosporine, when both medications are being used",
"        </p>",
"       </td>",
"       <td>",
"        Trough level 5 to 15 ng/mL; draw 7 days after any change",
"       </td>",
"       <td>",
"        <p>",
"         Metabolized by cytochrome P450 3A enzyme system",
"        </p>",
"        <p>",
"         Cytochrome P450 3A4 substrate, p-glycoprotein substrate",
"        </p>",
"        <p>",
"         Cyclosporine should be decreased by one-half to two-thirds when co-administered with sirolimus. If possible avoid tacrolimus with sirolimus",
"        </p>",
"        <p>",
"         Numerous clinically relevant interactions in transplant patients",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed wound healing",
"        </p>",
"        <p>",
"         Fatal airway anastomatic dehiscence if administered early after lung transplantation",
"        </p>",
"        <p>",
"         Myelosuppression",
"        </p>",
"        <p>",
"         Hypercholesterolemia",
"        </p>",
"        <p>",
"         Pulmonary toxicity",
"        </p>",
"        <p>",
"         LFT abnormalities",
"        </p>",
"        <p>",
"         Diarrhea",
"        </p>",
"        <p>",
"         Nausea",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Everolimus",
"       </td>",
"       <td>",
"        <p>",
"         Inhibits T cell proliferation by cell cycle arrest in G1 phase",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Everolimus is initiated at least three months post-transplantation, due to effects on wound healing",
"        </p>",
"        <p>",
"         Starting dose: 1.5 mg orally every 12 hours and adjusted to maintain a trough target between 3 and 12 ng/mL in combination with cyclosporine and a glucocorticoid",
"        </p>",
"       </td>",
"       <td>",
"        Goal trough level 3 to 12 ng/mL",
"       </td>",
"       <td>",
"        <p>",
"         Metabolized by cytochrome P450 3A enzyme system",
"        </p>",
"        <p>",
"         Cytochrome P450 3A4 substrate, p-glycoprotein substrate/inhibitor",
"        </p>",
"        <p>",
"         Calcineurin inhibitors should be decreased by one-half to two-thirds when co-administered with everolimus",
"        </p>",
"        <p>",
"         Numerous clinically relevant interactions in transplant patients",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed wound healing",
"        </p>",
"        <p>",
"         Bone marrow suppression",
"        </p>",
"        <p>",
"         Hypercholesterolemia",
"        </p>",
"        <p>",
"         Pulmonary toxicity",
"        </p>",
"        <p>",
"         Diarrhea",
"        </p>",
"        <p>",
"         Nausea",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GERD: gastroesophageal reflux disease; PUD: peptic ulcer disease; WBC: white blood cell count; CMV: cytomegalovirus; LFT: liver function tests; TPMT: thiopurine methyltransferase; mTOR: mammalian target of rapamycin.",
"     <br>",
"      * The US Food and Drug Administration has not approved any medications specifically for lung transplantation, so the doses are suggested based on the experience of large lung transplantation centers.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Immunosuppressants are subject to numerous drug interactions, particularly with drugs or foods that inhibit or induce CYP 450 3A4 and/or P-gp. Drug therapy should be managed by transplant specialists with expertise in therapeutic drug monitoring and doses adjusted based upon measurement of immunosuppressant concentrations, particularly whenever drug therapy is altered. The table is NOT a complete list of all possible interactions. See Lexi-Interact&trade; program included with UpToDate to check for other interactions, specific effects of interactions and managements suggestions.",
"       <br>",
"        &Delta; For additional information,&nbsp;refer to&nbsp;UpToDate topic on pharmacology and side effects of cyclosporine and tacrolimus.",
"        <br>",
"         &loz; For additional information, refer to UpToDate table on major drug interactions with immunosuppressants: cyclosporine, tacrolimus, sirolimus, or everolimus.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6:47.",
"     <br/>",
"     Korom S, et al. Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg 2009; 35:1045.",
"     <br/>",
"     Floreth T, Bhorade SM. Current trends in immunosuppression for lung transplantation. Semin Respir Crit Care Med 2010; 31:172.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_41_20127=[""].join("\n");
var outline_f19_41_20127=null;
